0001386570 false 12-31 Q2 2021 false 0.3333 0.3333 0.6667 0.6667 0001386570 2021-01-01 2021-06-30 xbrli:shares 0001386570 2021-08-02 iso4217:USD 0001386570 2021-06-30 0001386570 2020-12-31 iso4217:USD xbrli:shares 0001386570 2021-04-01 2021-06-30 0001386570 2020-04-01 2020-06-30 0001386570 2020-01-01 2020-06-30 0001386570 us-gaap:CommonStockMember 2021-03-31 0001386570 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001386570 us-gaap:RetainedEarningsMember 2021-03-31 0001386570 cdcx:CumulativeTranslationAdjustmentsMember 2021-03-31 0001386570 2021-03-31 0001386570 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001386570 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001386570 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001386570 us-gaap:CommonStockMember 2021-06-30 0001386570 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001386570 us-gaap:RetainedEarningsMember 2021-06-30 0001386570 cdcx:CumulativeTranslationAdjustmentsMember 2021-06-30 0001386570 us-gaap:CommonStockMember 2020-12-31 0001386570 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001386570 us-gaap:RetainedEarningsMember 2020-12-31 0001386570 cdcx:CumulativeTranslationAdjustmentsMember 2020-12-31 0001386570 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001386570 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001386570 cdcx:CumulativeTranslationAdjustmentsMember 2021-01-01 2021-06-30 0001386570 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001386570 us-gaap:CommonStockMember 2020-03-31 0001386570 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001386570 us-gaap:RetainedEarningsMember 2020-03-31 0001386570 cdcx:CumulativeTranslationAdjustmentsMember 2020-03-31 0001386570 2020-03-31 0001386570 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001386570 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001386570 cdcx:CumulativeTranslationAdjustmentsMember 2020-04-01 2020-06-30 0001386570 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001386570 us-gaap:CommonStockMember 2020-06-30 0001386570 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001386570 us-gaap:RetainedEarningsMember 2020-06-30 0001386570 cdcx:CumulativeTranslationAdjustmentsMember 2020-06-30 0001386570 2020-06-30 0001386570 us-gaap:CommonStockMember 2019-12-31 0001386570 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001386570 us-gaap:RetainedEarningsMember 2019-12-31 0001386570 cdcx:CumulativeTranslationAdjustmentsMember 2019-12-31 0001386570 2019-12-31 0001386570 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001386570 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001386570 cdcx:CumulativeTranslationAdjustmentsMember 2020-01-01 2020-06-30 0001386570 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001386570 cdcx:LiquidityMember 2021-01-01 2021-06-30 0001386570 cdcx:ShelfRegistrationMember 2020-06-30 0001386570 cdcx:AtTheMarketFacilityMember 2020-06-12 0001386570 cdcx:AtTheMarketFacilityMember 2021-04-01 2021-06-30 0001386570 cdcx:AtTheMarketFacilityMember 2021-06-30 0001386570 cdcx:StockOptionsMember 2021-04-01 2021-06-30 0001386570 cdcx:StockOptionsMember 2020-04-01 2020-06-30 0001386570 cdcx:StockOptionsMember 2021-01-01 2021-06-30 0001386570 cdcx:StockOptionsMember 2020-01-01 2020-06-30 0001386570 srt:AffiliatedEntityMember cdcx:ASWatsonGroupMember 2021-04-01 2021-06-30 0001386570 srt:AffiliatedEntityMember cdcx:ASWatsonGroupMember 2020-04-01 2020-06-30 0001386570 srt:AffiliatedEntityMember cdcx:ASWatsonGroupMember 2021-01-01 2021-06-30 0001386570 srt:AffiliatedEntityMember cdcx:ASWatsonGroupMember 2020-01-01 2020-06-30 0001386570 srt:AffiliatedEntityMember cdcx:ASWatsonGroupMember 2021-06-30 0001386570 srt:AffiliatedEntityMember cdcx:ASWatsonGroupMember 2020-12-31 0001386570 srt:AffiliatedEntityMember cdcx:HorizonVenturesMember 2021-04-01 2021-06-30 0001386570 srt:AffiliatedEntityMember cdcx:HorizonVenturesMember 2020-04-01 2020-06-30 0001386570 srt:AffiliatedEntityMember cdcx:HorizonVenturesMember 2021-01-01 2021-06-30 0001386570 srt:AffiliatedEntityMember cdcx:HorizonVenturesMember 2020-01-01 2020-06-30 0001386570 srt:AffiliatedEntityMember cdcx:HorizonVenturesMember 2021-06-30 0001386570 srt:AffiliatedEntityMember cdcx:HorizonVenturesMember 2020-12-31 0001386570 cdcx:AtTheMarketFacilityMember 2021-06-01 2021-06-30 0001386570 cdcx:SecuritiesPurchaseAgreementMember 2021-02-20 2021-02-20 0001386570 cdcx:SecuritiesPurchaseAgreementMember 2021-02-20 0001386570 cdcx:SecuritiesPurchaseAgreementMember 2021-02-23 2021-02-23 cdcx:renewal_options xbrli:pure 0001386570 cdcx:A2017EquityIncentivePlanMember 2021-06-30 0001386570 cdcx:ShareBasedPaymentArrangementOptionOrStockAppreciationRightMember 2021-06-30 0001386570 cdcx:FullValueAwardMember 2021-06-30 0001386570 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001386570 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-06-30 0001386570 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-06-30 0001386570 cdcx:ServicePeriodBasedStockOptionsMember 2020-12-31 0001386570 cdcx:ServicePeriodBasedStockOptionsMember 2020-01-01 2020-12-31 0001386570 cdcx:ServicePeriodBasedStockOptionsMember 2021-01-01 2021-06-30 0001386570 cdcx:ServicePeriodBasedStockOptionsMember 2021-06-30 0001386570 cdcx:PerformanceBasedStockOptionsMember 2020-12-31 0001386570 cdcx:PerformanceBasedStockOptionsMember 2020-01-01 2020-12-31 0001386570 cdcx:PerformanceBasedStockOptionsMember 2021-01-01 2021-06-30 0001386570 cdcx:PerformanceBasedStockOptionsMember 2021-06-30 0001386570 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-06-30 0001386570 us-gaap:ShareBasedCompensationAwardTrancheTwoMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001386570 us-gaap:CostOfSalesMember 2021-04-01 2021-06-30 0001386570 us-gaap:CostOfSalesMember 2020-04-01 2020-06-30 0001386570 us-gaap:CostOfSalesMember 2021-01-01 2021-06-30 0001386570 us-gaap:CostOfSalesMember 2020-01-01 2020-06-30 0001386570 cdcx:SalesAndMarketingMember 2021-04-01 2021-06-30 0001386570 cdcx:SalesAndMarketingMember 2020-04-01 2020-06-30 0001386570 cdcx:SalesAndMarketingMember 2021-01-01 2021-06-30 0001386570 cdcx:SalesAndMarketingMember 2020-01-01 2020-06-30 0001386570 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001386570 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001386570 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001386570 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001386570 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001386570 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001386570 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001386570 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 cdcx:reportable_segment 0001386570 us-gaap:OperatingSegmentsMember cdcx:ConsumerProductsSegmentMember 2021-04-01 2021-06-30 0001386570 cdcx:IngredientsSegmentMember us-gaap:OperatingSegmentsMember 2021-04-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember us-gaap:OperatingSegmentsMember 2021-04-01 2021-06-30 0001386570 cdcx:CorporateAndReconcilingItemsMember 2021-04-01 2021-06-30 0001386570 us-gaap:OperatingSegmentsMember cdcx:ConsumerProductsSegmentMember 2020-04-01 2020-06-30 0001386570 cdcx:IngredientsSegmentMember us-gaap:OperatingSegmentsMember 2020-04-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember us-gaap:OperatingSegmentsMember 2020-04-01 2020-06-30 0001386570 cdcx:CorporateAndReconcilingItemsMember 2020-04-01 2020-06-30 0001386570 us-gaap:OperatingSegmentsMember cdcx:ConsumerProductsSegmentMember 2021-01-01 2021-06-30 0001386570 cdcx:IngredientsSegmentMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-06-30 0001386570 cdcx:CorporateAndReconcilingItemsMember 2021-01-01 2021-06-30 0001386570 us-gaap:OperatingSegmentsMember cdcx:ConsumerProductsSegmentMember 2020-01-01 2020-06-30 0001386570 cdcx:IngredientsSegmentMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-06-30 0001386570 cdcx:CorporateAndReconcilingItemsMember 2020-01-01 2020-06-30 0001386570 us-gaap:OperatingSegmentsMember cdcx:ConsumerProductsSegmentMember 2021-06-30 0001386570 cdcx:IngredientsSegmentMember us-gaap:OperatingSegmentsMember 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember us-gaap:OperatingSegmentsMember 2021-06-30 0001386570 cdcx:CorporateAndReconcilingItemsMember 2021-06-30 0001386570 us-gaap:OperatingSegmentsMember cdcx:ConsumerProductsSegmentMember 2020-12-31 0001386570 cdcx:IngredientsSegmentMember us-gaap:OperatingSegmentsMember 2020-12-31 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember us-gaap:OperatingSegmentsMember 2020-12-31 0001386570 cdcx:CorporateAndReconcilingItemsMember 2020-12-31 0001386570 cdcx:ConsumerProductsSegmentMember cdcx:TRUNIAGENConsumerProductMember 2021-04-01 2021-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:TRUNIAGENConsumerProductMember 2021-04-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:TRUNIAGENConsumerProductMember 2021-04-01 2021-06-30 0001386570 cdcx:TRUNIAGENConsumerProductMember 2021-04-01 2021-06-30 0001386570 cdcx:NIAGENIngredientMember cdcx:ConsumerProductsSegmentMember 2021-04-01 2021-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:NIAGENIngredientMember 2021-04-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:NIAGENIngredientMember 2021-04-01 2021-06-30 0001386570 cdcx:NIAGENIngredientMember 2021-04-01 2021-06-30 0001386570 cdcx:NIAGENRelatedMember cdcx:ConsumerProductsSegmentMember 2021-04-01 2021-06-30 0001386570 cdcx:NIAGENRelatedMember cdcx:IngredientsSegmentMember 2021-04-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:NIAGENRelatedMember 2021-04-01 2021-06-30 0001386570 cdcx:NIAGENRelatedMember 2021-04-01 2021-06-30 0001386570 cdcx:OtherIngredientsMember cdcx:ConsumerProductsSegmentMember 2021-04-01 2021-06-30 0001386570 cdcx:OtherIngredientsMember cdcx:IngredientsSegmentMember 2021-04-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:OtherIngredientsMember 2021-04-01 2021-06-30 0001386570 cdcx:OtherIngredientsMember 2021-04-01 2021-06-30 0001386570 cdcx:ReferenceStandardsMember cdcx:ConsumerProductsSegmentMember 2021-04-01 2021-06-30 0001386570 cdcx:ReferenceStandardsMember cdcx:IngredientsSegmentMember 2021-04-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:ReferenceStandardsMember 2021-04-01 2021-06-30 0001386570 cdcx:ReferenceStandardsMember 2021-04-01 2021-06-30 0001386570 cdcx:ConsumerProductsSegmentMember cdcx:ConsultingAndOtherMember 2021-04-01 2021-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:ConsultingAndOtherMember 2021-04-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:ConsultingAndOtherMember 2021-04-01 2021-06-30 0001386570 cdcx:ConsultingAndOtherMember 2021-04-01 2021-06-30 0001386570 cdcx:OtherGoodsAndServicesMember cdcx:ConsumerProductsSegmentMember 2021-04-01 2021-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:OtherGoodsAndServicesMember 2021-04-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:OtherGoodsAndServicesMember 2021-04-01 2021-06-30 0001386570 cdcx:OtherGoodsAndServicesMember 2021-04-01 2021-06-30 0001386570 cdcx:ConsumerProductsSegmentMember 2021-04-01 2021-06-30 0001386570 cdcx:IngredientsSegmentMember 2021-04-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember 2021-04-01 2021-06-30 0001386570 cdcx:ConsumerProductsSegmentMember cdcx:TRUNIAGENConsumerProductMember 2020-04-01 2020-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:TRUNIAGENConsumerProductMember 2020-04-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:TRUNIAGENConsumerProductMember 2020-04-01 2020-06-30 0001386570 cdcx:TRUNIAGENConsumerProductMember 2020-04-01 2020-06-30 0001386570 cdcx:NIAGENIngredientMember cdcx:ConsumerProductsSegmentMember 2020-04-01 2020-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:NIAGENIngredientMember 2020-04-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:NIAGENIngredientMember 2020-04-01 2020-06-30 0001386570 cdcx:NIAGENIngredientMember 2020-04-01 2020-06-30 0001386570 cdcx:NIAGENRelatedMember cdcx:ConsumerProductsSegmentMember 2020-04-01 2020-06-30 0001386570 cdcx:NIAGENRelatedMember cdcx:IngredientsSegmentMember 2020-04-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:NIAGENRelatedMember 2020-04-01 2020-06-30 0001386570 cdcx:NIAGENRelatedMember 2020-04-01 2020-06-30 0001386570 cdcx:OtherIngredientsMember cdcx:ConsumerProductsSegmentMember 2020-04-01 2020-06-30 0001386570 cdcx:OtherIngredientsMember cdcx:IngredientsSegmentMember 2020-04-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:OtherIngredientsMember 2020-04-01 2020-06-30 0001386570 cdcx:OtherIngredientsMember 2020-04-01 2020-06-30 0001386570 cdcx:ReferenceStandardsMember cdcx:ConsumerProductsSegmentMember 2020-04-01 2020-06-30 0001386570 cdcx:ReferenceStandardsMember cdcx:IngredientsSegmentMember 2020-04-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:ReferenceStandardsMember 2020-04-01 2020-06-30 0001386570 cdcx:ReferenceStandardsMember 2020-04-01 2020-06-30 0001386570 cdcx:ConsumerProductsSegmentMember cdcx:ConsultingAndOtherMember 2020-04-01 2020-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:ConsultingAndOtherMember 2020-04-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:ConsultingAndOtherMember 2020-04-01 2020-06-30 0001386570 cdcx:ConsultingAndOtherMember 2020-04-01 2020-06-30 0001386570 cdcx:OtherGoodsAndServicesMember cdcx:ConsumerProductsSegmentMember 2020-04-01 2020-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:OtherGoodsAndServicesMember 2020-04-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:OtherGoodsAndServicesMember 2020-04-01 2020-06-30 0001386570 cdcx:OtherGoodsAndServicesMember 2020-04-01 2020-06-30 0001386570 cdcx:ConsumerProductsSegmentMember 2020-04-01 2020-06-30 0001386570 cdcx:IngredientsSegmentMember 2020-04-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember 2020-04-01 2020-06-30 0001386570 cdcx:ConsumerProductsSegmentMember cdcx:TRUNIAGENConsumerProductMember 2021-01-01 2021-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:TRUNIAGENConsumerProductMember 2021-01-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:TRUNIAGENConsumerProductMember 2021-01-01 2021-06-30 0001386570 cdcx:TRUNIAGENConsumerProductMember 2021-01-01 2021-06-30 0001386570 cdcx:NIAGENIngredientMember cdcx:ConsumerProductsSegmentMember 2021-01-01 2021-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:NIAGENIngredientMember 2021-01-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:NIAGENIngredientMember 2021-01-01 2021-06-30 0001386570 cdcx:NIAGENIngredientMember 2021-01-01 2021-06-30 0001386570 cdcx:NIAGENRelatedMember cdcx:ConsumerProductsSegmentMember 2021-01-01 2021-06-30 0001386570 cdcx:NIAGENRelatedMember cdcx:IngredientsSegmentMember 2021-01-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:NIAGENRelatedMember 2021-01-01 2021-06-30 0001386570 cdcx:NIAGENRelatedMember 2021-01-01 2021-06-30 0001386570 cdcx:OtherIngredientsMember cdcx:ConsumerProductsSegmentMember 2021-01-01 2021-06-30 0001386570 cdcx:OtherIngredientsMember cdcx:IngredientsSegmentMember 2021-01-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:OtherIngredientsMember 2021-01-01 2021-06-30 0001386570 cdcx:OtherIngredientsMember 2021-01-01 2021-06-30 0001386570 cdcx:ReferenceStandardsMember cdcx:ConsumerProductsSegmentMember 2021-01-01 2021-06-30 0001386570 cdcx:ReferenceStandardsMember cdcx:IngredientsSegmentMember 2021-01-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:ReferenceStandardsMember 2021-01-01 2021-06-30 0001386570 cdcx:ReferenceStandardsMember 2021-01-01 2021-06-30 0001386570 cdcx:ConsumerProductsSegmentMember cdcx:ConsultingAndOtherMember 2021-01-01 2021-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:ConsultingAndOtherMember 2021-01-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:ConsultingAndOtherMember 2021-01-01 2021-06-30 0001386570 cdcx:ConsultingAndOtherMember 2021-01-01 2021-06-30 0001386570 cdcx:OtherGoodsAndServicesMember cdcx:ConsumerProductsSegmentMember 2021-01-01 2021-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:OtherGoodsAndServicesMember 2021-01-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:OtherGoodsAndServicesMember 2021-01-01 2021-06-30 0001386570 cdcx:OtherGoodsAndServicesMember 2021-01-01 2021-06-30 0001386570 cdcx:ConsumerProductsSegmentMember 2021-01-01 2021-06-30 0001386570 cdcx:IngredientsSegmentMember 2021-01-01 2021-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember 2021-01-01 2021-06-30 0001386570 cdcx:ConsumerProductsSegmentMember cdcx:TRUNIAGENConsumerProductMember 2020-01-01 2020-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:TRUNIAGENConsumerProductMember 2020-01-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:TRUNIAGENConsumerProductMember 2020-01-01 2020-06-30 0001386570 cdcx:TRUNIAGENConsumerProductMember 2020-01-01 2020-06-30 0001386570 cdcx:NIAGENIngredientMember cdcx:ConsumerProductsSegmentMember 2020-01-01 2020-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:NIAGENIngredientMember 2020-01-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:NIAGENIngredientMember 2020-01-01 2020-06-30 0001386570 cdcx:NIAGENIngredientMember 2020-01-01 2020-06-30 0001386570 cdcx:NIAGENRelatedMember cdcx:ConsumerProductsSegmentMember 2020-01-01 2020-06-30 0001386570 cdcx:NIAGENRelatedMember cdcx:IngredientsSegmentMember 2020-01-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:NIAGENRelatedMember 2020-01-01 2020-06-30 0001386570 cdcx:NIAGENRelatedMember 2020-01-01 2020-06-30 0001386570 cdcx:OtherIngredientsMember cdcx:ConsumerProductsSegmentMember 2020-01-01 2020-06-30 0001386570 cdcx:OtherIngredientsMember cdcx:IngredientsSegmentMember 2020-01-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:OtherIngredientsMember 2020-01-01 2020-06-30 0001386570 cdcx:OtherIngredientsMember 2020-01-01 2020-06-30 0001386570 cdcx:ReferenceStandardsMember cdcx:ConsumerProductsSegmentMember 2020-01-01 2020-06-30 0001386570 cdcx:ReferenceStandardsMember cdcx:IngredientsSegmentMember 2020-01-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:ReferenceStandardsMember 2020-01-01 2020-06-30 0001386570 cdcx:ReferenceStandardsMember 2020-01-01 2020-06-30 0001386570 cdcx:ConsumerProductsSegmentMember cdcx:ConsultingAndOtherMember 2020-01-01 2020-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:ConsultingAndOtherMember 2020-01-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:ConsultingAndOtherMember 2020-01-01 2020-06-30 0001386570 cdcx:ConsultingAndOtherMember 2020-01-01 2020-06-30 0001386570 cdcx:OtherGoodsAndServicesMember cdcx:ConsumerProductsSegmentMember 2020-01-01 2020-06-30 0001386570 cdcx:IngredientsSegmentMember cdcx:OtherGoodsAndServicesMember 2020-01-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember cdcx:OtherGoodsAndServicesMember 2020-01-01 2020-06-30 0001386570 cdcx:OtherGoodsAndServicesMember 2020-01-01 2020-06-30 0001386570 cdcx:ConsumerProductsSegmentMember 2020-01-01 2020-06-30 0001386570 cdcx:IngredientsSegmentMember 2020-01-01 2020-06-30 0001386570 cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember 2020-01-01 2020-06-30 0001386570 srt:AffiliatedEntityMember us-gaap:SalesRevenueNetMember cdcx:ASWatsonGroupMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001386570 srt:AffiliatedEntityMember us-gaap:SalesRevenueNetMember cdcx:ASWatsonGroupMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001386570 srt:AffiliatedEntityMember us-gaap:SalesRevenueNetMember cdcx:ASWatsonGroupMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0001386570 srt:AffiliatedEntityMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cdcx:HorizonVenturesMember 2020-04-01 2020-06-30 0001386570 srt:AffiliatedEntityMember us-gaap:AccountsReceivableMember cdcx:ASWatsonGroupMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001386570 srt:AffiliatedEntityMember us-gaap:AccountsReceivableMember cdcx:ASWatsonGroupMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001386570 us-gaap:AccountsReceivableMember cdcx:WalmartMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001386570 us-gaap:AccountsReceivableMember cdcx:MatakanaHealthMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001386570 us-gaap:AccountsReceivableMember cdcx:MatakanaHealthMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001386570 cdcx:LifeExtensionMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001386570 cdcx:AmazonMarketplacesMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001386570 cdcx:CaliforniaActionMember 2019-08-16 2019-08-16 0001386570 cdcx:RejuvenationTherapeuticsMember 2020-09-15 2020-09-15 0001386570 cdcx:RejuvenationTherapeuticsMember 2021-06-30 0001386570 2019-09-30 0001386570 us-gaap:SubsequentEventMember us-gaap:InventoriesMember 2021-08-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2021
Commission File Number: 001-37752

| CHROMADEX CORPORATION |
| (Exact Name of Registrant as Specified in its Charter) |

Delaware |  | 26-2940963
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
10900 Wilshire Blvd. Suite 600, Los Angeles, California |  | 90024
(Address of Principal Executive Offices) |  | (Zip Code)

Registrant's telephone number, including area code: (310) 388-6706
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of Each exchange on which registered
Common Stock, $0.001 par value per share | CDXC | The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. | ☑ | Yes | ☐ | No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). | ☑ | Yes | ☐ | No
Indicate by check mark whether the registrant is a large accelerated filer, accelerated filer, non-accelerated filer, smaller reporting company or emerging growth company. See definition of “large accelerated filer, accelerated filer, smaller reporting company and emerging growth company” in Rule 12b-2 of the Exchange Act. |  |  |  |
Large accelerated filer | ☐ | Accelerated filer | ☐ | Non-accelerated filer | ☑ | Smaller reporting company | ☑ | Emerging growth company | ☐ |  |  |  |
If an emerging growth company, indicate if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | Yes | ☐ | No
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). | ☐ | Yes | ☑ | No

As of August 2, 2021 there were 68,196,526 shares of the registrant’s common stock issued and outstanding.

CHROMADEX CORPORATION
QUARTERLY REPORT ON FORM 10-Q
TABLE OF CONTENTS

PART I - Financial Information (unaudited) | Pg.
Item 1. Financial Statements (unaudited): | 5
Condensed Consolidated Balance Sheets as of June 30, 2021 and December 31, 2020 | 5
Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2021 and June 30, 2020. | 6
Condensed Consolidated Statements of Stockholders Equity for the three and six months ended June 30, 2021 and June 30, 2020 | 7
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2021 and June 30, 2020 | 9
Notes to Condensed Consolidated Financial Statements | 10
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 25
Item 3. Quantitative and Qualitative Disclosures About Market Risk | 32
Item 4. Controls and Procedures | 33
PART II - Other Information |
Item 1. Legal Proceedings | 34
Item 1A. Risk Factors | 34
Item 2. Unregistered sales of equity securities and use of proceeds | 52
Item 3. Defaults upon senior securities | 52
Item 4. Mine safety disclosures | 52
Item 5. Other information | 52
Item 6. Exhibits | 53
Signatures | 55

2

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements that involve risks and uncertainties. Chromadex Corporation makes such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could," "predicts," "projects," "continue," "would" or the negative of such terms or other similar expressions. These forward-looking statements include, but are not limited to, statements relating to our business, business strategy, products and services we may offer in the future, the outcome and impact of litigation, the timing and results of future regulatory filings, the timing and results of future clinical trials, our ability to collect from major customers, sales and marketing strategy and capital outlook.
Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part II, Item 1A, “Risk Factors” of this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
Unless the context otherwise indicates, references in this Quarterly Report to the terms “ChromaDex”, “the Company”, “we,” “our, and “us” refer to ChromaDex Corporation and its wholly-owned subsidiaries.
3

Table of Contents
SUMMARY OF RISK FACTORS
An investment in shares of our common stock involves a high degree of risk. Below is a list of the more significant risks associated with our business. This summary does not address all of the risks that we face. Additional discussion of the risks listed in this summary, as well as other risks that we face, are set forth under Part I, Item 1A, “Risk Factors” in this Quarterly Report. Some of the material risks associated with our business include the following:
▪The COVID-19 pandemic has adversely affected, and is expected to continue to pose risks to our business, results of operations, financial condition and cash flows, and other epidemics or outbreaks of infectious diseases may have a similar impact.
▪We have a history of operating losses, may need additional financing to meet our future long-term capital requirements and may be unable to raise sufficient capital on favorable terms or at all.
▪Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain and may be inadequate, which would pose risks to our business, results of operations, financial condition and cash flows.
▪We are currently engaged in substantial and complex litigation with Elysium Health, Inc. and Elysium Health LLC (collectively, “Elysium”), the outcome of which could materially harm our business, results of operations, financial condition and cash flows.
▪Our TRU NIAGEN® products are not approved by the United States Food and Drug Administration or any foreign regulatory authority to mitigate, prevent, treat, diagnose or cure COVID-19 or any other disease or condition.
▪The future growth and profitability of our consumer product business will depend in large part upon the effectiveness and efficiency of our marketing efforts and our ability to select effective markets and media in which to market and advertise.
▪Unfavorable publicity or consumer perception of our products and any similar products distributed by other companies could have a material adverse effect on our business, results of operations, financial condition and cash flows.
▪Our operating results may fluctuate significantly as a result of a variety of factors, many of which are outside of our control.
▪We rely on single or a limited number of third-party suppliers for the raw materials required to produce our products.
▪Any inability to maintain sales, marketing and distribution capabilities or maintain arrangements with third parties to sell, market and distribute our products, would pose risks to our business, results of operations, financial condition and cash flows.
▪Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.
▪Government regulations of our customer’s business are extensive and are constantly changing. Changes in these regulations can significantly affect customer demand for our products and services.
▪The market price of our common stock may be volatile and adversely affected by several factors.
▪We have not paid cash dividends in the past and do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.
▪We have a significant number of outstanding options. Future sales of these shares could adversely affect the market price of our common stock.
▪We may become involved in securities class action litigation that could divert management’s attention and harm our business, results of operations, financial condition and cash flows.
4

Table of Contents
PART I
Item 1. FINANCIAL STATEMENTS (unaudited)
ChromaDex Corporation and Subsidiaries
Unaudited Condensed Consolidated Balance Sheets

| Jun 30, 2021 |  | Dec 31, 2020
(In thousands except par values, unless otherwise indicated)
Assets |  |  |
Current assets |  |  |
Cash, including restricted cash of $0.2 million for both periods | $ | 38,778 |  |  | $ | 16,697 |
Trade receivables, net of allowances of $0.1 million and $0.2 million, respectively; Including receivables from Related Party of: $2.2 million and $0.9 million, respectively. | 5,999 |  |  | 2,694 |
Inventories | 12,183 |  |  | 11,683 |
Prepaid expenses and other assets | 972 |  |  | 1,145 |
Total current assets | 57,932 |  |  | 32,219 |
Leasehold improvements and equipment, net | 3,150 |  |  | 3,206 |
Intangible assets, net | 961 |  |  | 1,082 |
Right-of-use assets | 3,182 |  |  | 1,226 |
Other long-term assets | 617 |  |  | 625 |
Total assets | $ | 65,842 |  |  | $ | 38,358 |
Liabilities and Stockholders' Equity |  |  |
Current liabilities |  |  |
Accounts payable | $ | 9,970 |  |  | $ | 9,445 |
Accrued expenses | 5,569 |  |  | 6,133 |
Current maturities of operating lease obligations | 467 |  |  | 589 |
Current maturities of finance lease obligations | 13 |  |  | 31 |
Customer deposits | 210 |  |  | 278 |
Total current liabilities | 16,229 |  |  | 16,476 |
Deferred revenue | 4,441 |  |  | 4,441 |
Operating lease obligations, less current maturities | 3,017 |  |  | 997 |
Finance lease obligations, less current maturities | 13 |  |  | 20 |
Total liabilities | 23,700 |  |  | 21,934 |
Commitments and Contingencies |  |  |
Stockholders' Equity |  |  |
Common stock, $0.001 par value; authorized 150,000 shares; 68,009 shares and 61,881 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively. | 68 |  |  | 62 |
Additional paid-in capital | 196,848 |  |  | 158,190 |
Accumulated deficit | (154,772) |  |  | (141,825) |
Cumulative translation adjustments | (2) |  |  | (3) |
Total stockholders' equity | 42,142 |  |  | 16,424 |
Total liabilities and stockholders' equity | $ | 65,842 |  |  | $ | 38,358 |

See accompanying notes to consolidated financial statements.
5

Table of Contents
ChromaDex Corporation and Subsidiaries
Unaudited Condensed Consolidated Statements of Operations

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
(In thousands, except per share data) |  |  |  |  |  |  |
Sales, net | $ | 17,699 |  |  | $ | 15,287 |  |  | $ | 32,382 |  |  | $ | 29,632 |
Cost of sales | 6,889 |  |  | 6,199 |  |  | 12,338 |  |  | 12,233 |
Gross profit | 10,810 |  |  | 9,088 |  |  | 20,044 |  |  | 17,399 |
Operating expenses: |  |  |  |  |  |  |
Sales and marketing | 6,232 |  |  | 4,959 |  |  | 12,490 |  |  | 9,406 |
Research and development | 1,004 |  |  | 895 |  |  | 1,791 |  |  | 1,704 |
General and administrative | 9,128 |  |  | 6,921 |  |  | 18,679 |  |  | 15,866 |
Total operating expenses | 16,364 |  |  | 12,775 |  |  | 32,960 |  |  | 26,976 |
Operating loss | (5,554) |  |  | (3,687) |  |  | (12,916) |  |  | (9,577) |
Interest expense, net | (12) |  |  | (24) |  |  | (31) |  |  | (36) |
Net loss | $ | (5,566) |  |  | $ | (3,711) |  |  | $ | (12,947) |  |  | $ | (9,613) |
Basic and diluted loss per common share | $ | (0.08) |  |  | $ | (0.06) |  |  | $ | (0.20) |  |  | $ | (0.16) |
Basic and diluted weighted average common shares outstanding | 67,986 |  |  | 60,906 |  |  | 66,086 |  |  | 60,344 |

See accompanying notes to consolidated financial statements.
6

Table of Contents
ChromaDex Corporation and Subsidiaries
Unaudited Condensed Consolidated Statement of Stockholders' Equity
(In thousands)

| Three Months Ended June 30, 2021
| Common Stock |  | Additional Paid-in Capital |  | Accumulated Deficit |  | Cumulative Translation Adjustments |  | Total Stockholders' Equity
| Shares |  | Amount |  |  |  |
Balance, March 31, 2021 | 67,702 |  |  | $ | 68 |  |  | $ | 192,972 |  |  | $ | (149,206) |  |  | $ | (2) |  |  | $ | 43,832 |
Issuance of common stock, net of offering costs of $0.3 million | 213 |  |  | — |  |  | 1,869 |  |  | — |  |  | — |  |  | 1,869 |
Exercise of stock options | 94 |  |  | — |  |  | 391 |  |  | — |  |  | — |  |  | 391 |
Share-based compensation | — |  |  | — |  |  | 1,616 |  |  | — |  |  | — |  |  | 1,616 |
Translation adjustment | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Net loss | — |  |  | — |  |  | — |  |  | (5,566) |  |  | — |  |  | (5,566) |
Balance, June 30, 2021 | 68,009 |  |  | $ | 68 |  |  | $ | 196,848 |  |  | $ | (154,772) |  |  | $ | (2) |  |  | $ | 42,142 |

| Six Months Ended June 30, 2021
| Common Stock |  | Additional Paid-in Capital |  | Accumulated Deficit |  | Cumulative Translation Adjustments |  | Total Stockholders' Equity
| Shares |  | Amount |  |  |  |
Balance, January 1, 2021 | 61,881 |  |  | $ | 62 |  |  | $ | 158,190 |  |  | $ | (141,825) |  |  | $ | (3) |  |  | $ | 16,424 |
Issuance of common stock, net of offering costs of $0.4 million | 4,059 |  |  | 4 |  |  | 26,736 |  |  | — |  |  | — |  |  | 26,740 |
Exercise of stock options | 2,069 |  |  | 2 |  |  | 9,022 |  |  | — |  |  | — |  |  | 9,024 |
Share-based compensation | — |  |  | — |  |  | 2,900 |  |  | — |  |  | — |  |  | 2,900 |
Translation adjustment | — |  |  | — |  |  | — |  |  | — |  |  | 1 |  |  | 1 |
Net loss | — |  |  | — |  |  | — |  |  | (12,947) |  |  | — |  |  | (12,947) |
Balance, June 30, 2021 | 68,009 |  |  | $ | 68 |  |  | $ | 196,848 |  |  | $ | (154,772) |  |  | $ | (2) |  |  | $ | 42,142 |

7

Table of Contents
ChromaDex Corporation and Subsidiaries
Unaudited Condensed Consolidated Statement of Stockholders' Equity - (continued)
(In thousands)

| Three Months Ended June 30, 2020
| Common Stock |  | Additional Paid-in Capital |  | Accumulated Deficit |  | Cumulative Translation Adjustments |  | Total Stockholders' Equity
| Shares |  | Amount |  |  |  |
Balance, March 31, 2020 | 59,605 |  |  | $ | 60 |  |  | $ | 144,290 |  |  | $ | (127,802) |  |  | $ | — |  |  | $ | 16,548 |
Issuance of common stock, net of offering costs of $0.1 million | 1,225 |  |  | 1 |  |  | 4,855 |  |  |  |  |  |  | 4,856 |
Exercise of stock options | 591 |  |  | — |  |  | 2,180 |  |  | — |  |  | — |  |  | 2,180 |
Share-based compensation | — |  |  | — |  |  | 1,711 |  |  | — |  |  | — |  |  | 1,711 |
Translation adjustment | — |  |  | — |  |  | — |  |  | — |  |  | (3) |  |  | (3) |
Net loss | — |  |  | — |  |  | — |  |  | (3,711) |  |  |  |  | (3,711) |
Balance, June 30, 2020 | 61,421 |  |  | $ | 61 |  |  | $ | 153,036 |  |  | $ | (131,513) |  |  | $ | (3) |  |  | $ | 21,581 |

| Six Months Ended June 30, 2020
| Common Stock |  | Additional Paid-in Capital |  | Accumulated Deficit |  | Cumulative Translation Adjustments |  | Total Stockholders' Equity
| Shares |  | Amount |  |  |  |
Balance, January 1, 2020 | 59,562 |  |  | $ | 60 |  |  | $ | 142,285 |  |  | $ | (121,900) |  |  | $ | — |  |  | $ | 20,445 |
Issuance of common stock, net of offering costs of $0.1 million | 1,225 |  |  | 1 |  |  | 4,855 |  |  |  |  |  |  | 4,856 |
Exercise of stock options | 634 |  |  | — |  |  | 2,312 |  |  | — |  |  | — |  |  | 2,312 |
Share-based compensation | — |  |  | — |  |  | 3,584 |  |  | — |  |  | — |  |  | 3,584 |
Translation adjustment | — |  |  | — |  |  | — |  |  | — |  |  | (3) |  |  | (3) |
Net loss | — |  |  | — |  |  | — |  |  | (9,613) |  |  |  |  | (9,613) |
Balance, June 30, 2020 | 61,421 |  |  | $ | 61 |  |  | $ | 153,036 |  |  | $ | (131,513) |  |  | $ | (3) |  |  | $ | 21,581 |

See accompanying notes to consolidated financial statements.
8

Table of Contents
ChromaDex Corporation and Subsidiaries
Unaudited Condensed Consolidated Statements of Cash Flows

| Six Months Ended June 30,
| 2021 |  | 2020
| (In thousands)
Cash Flows From Operating Activities |  |  |
Net loss | $ | (12,947) |  |  | $ | (9,613) |
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
Depreciation of leasehold improvements and equipment | 447 |  |  | 432 |
Amortization of intangibles | 121 |  |  | 122 |
Amortization of right of use assets | 254 |  |  | 187 |
Share-based compensation expense | 2,900 |  |  | 3,584 |
Change in allowance for doubtful trade receivables | 26 |  |  | (2,730) |
Non-cash financing costs | 57 |  |  | 51 |
Changes in operating assets and liabilities: |  |  |
Trade receivables | (3,331) |  |  | 952 |
Inventories | (500) |  |  | (804) |
Implementation costs for cloud computing arrangement | (79) |  |  | — |
Prepaid expenses and other assets | 171 |  |  | 322 |
Accounts payable | 525 |  |  | 154 |
Accrued expenses | (564) |  |  | 830 |
Deferred revenue | — |  |  | (53) |
Customer deposits and other | (68) |  |  | 78 |
Principal payments on operating leases | (312) |  |  | (289) |
Net cash used in operating activities | (13,300) |  |  | (6,777) |
Cash Flows From Investing Activities |  |  |
Purchases of leasehold improvements and equipment | (311) |  |  | (107) |
Investment in other long-term assets | — |  |  | (15) |
Net cash used in investing activities | (311) |  |  | (122) |
Cash Flows From Financing Activities |  |  |
Proceeds from issuance of common stock, net | 26,740 |  |  | 4,856 |
Proceeds from exercise of stock options | 9,024 |  |  | 2,312 |
Payment of debt issuance costs | (47) |  |  | (30) |
Principal payments on finance leases | (25) |  |  | (161) |
Net cash provided by financing activities | 35,692 |  |  | 6,977 |
Net increase in cash | 22,081 |  |  | 78 |
Cash, including restricted cash of $0.2 million for both 2021 and 2020 - beginning of period | 16,697 |  |  | 18,812 |
Cash, including restricted cash of $0.2 million for both 2021 and 2020 - end of period | $ | 38,778 |  |  | $ | 18,890 |
Supplemental Disclosures of Cash Flow Information |  |  |
Cash payments for interest on finance leases | $ | 1 |  |  | $ | 9 |
Supplemental Schedule of Noncash Operating Activity |  |  |
Right-of-use assets and operating lease obligations incurred for entering into lease amendment | $ | 2,209 |  |  | $ | — |
Supplemental Schedule of Noncash Investing Activity |  |  |
Financing lease obligation incurred for purchase of computer equipment and software | $ | — |  |  | $ | 47 |

See accompanying notes to consolidated financial statements.
9

Table of Contents
Note 1. Interim Financial Statements
The accompanying financial statements of ChromaDex Corporation and its wholly-owned subsidiaries, ChromaDex, Inc., ChromaDex Analytics, Inc., ChromaDex Asia Limited and ChromaDex Europa B.V. (collectively referred to herein as “ChromaDex” or the “Company”) include all adjustments, consisting of normal recurring adjustments and accruals, that, in the opinion of the management of the Company, are necessary for a fair presentation of the Company’s financial position as of June 30, 2021 and results of operations and cash flows for the three and six months ended June 30, 2021 and June 30, 2020. These unaudited interim financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2020 appearing in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on March 12, 2021. Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be achieved for the full year ending on December 31, 2021. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
The balance sheet at December 31, 2020 has been derived from the audited financial statements at that date. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with GAAP have been condensed or omitted.
Note 2. Nature of Business
ChromaDex is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (“NAD+”), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (“NR”), commercialized as the flagship ingredient NIAGEN®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex delivers NIAGEN® as the sole active ingredient in its consumer product TRU NIAGEN®. The Company also has analytical reference standards and services segment, which focuses on natural product fine chemicals (known as “phytochemicals”) and related chemistry services.
Note 3. Liquidity
The Company's net cash outflow from operating activities was approximately $13.3 million for the six months ended June 30, 2021. As of June 30, 2021, cash and cash equivalents totaled approximately $38.8 million, which includes restricted cash of approximately $0.2 million.
The Company anticipates that its current cash, cash equivalents, and available line of credit up to $7.0 million from Western Alliance Bank will be sufficient to meet its projected operating plans through at least the next twelve months from the issuance date of these financial statements. The Company may, however, seek additional capital within the next twelve months, both to meet its projected operating plans within the next twelve months and/or to fund its longer-term strategic objectives. In June 2020, the Company filed a $125 million registration statement on Form S-3 with the Commission, utilizing a “shelf” registration process. Under this shelf registration process, the Company may sell securities from time to time, including up to $50 million pursuant to the At Market Issuance Sales Agreement, dated as of June 12, 2020, with B. Riley FBR, Inc. and Raymond James & Associates, Inc. (the “ATM Facility”). During the three months ended June 30, 2021, the Company sold an aggregate of 0.2 million shares of its common stock under the ATM Facility resulting in proceeds of $1.9 million, net of offering costs of $0.3 million. The shares sold at an average price of $10.56 per share. As of June 30, 2021, approximately $47.8 million remains available under the ATM Facility.
Note 4. Significant Accounting Policies
Basis of Presentation: The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company’s fiscal year ends on December 31.
Reclassifications — Certain prior period results have been reclassified to be consistent with the current period presentation.
10

Table of Contents
Recent Accounting Pronouncements: In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard’s main goal is to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new guidance represents significant changes to accounting for credit losses: (i) full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope; (ii) the current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold; and (iii) the expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts. ASU 2016-13 introduces two distinctive credit loss impairment models: (i) current expected credit loss impairment model (Subtopic 326-20) applicable to financial assets measured at amortized cost; and (ii) available-for-sale debt securities impairment model (Subtopic 326-30). ASU 2016-13 is effective for public entities for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Public entities that qualify as a smaller reporting company can elect to defer compliance effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact of ASU 2016-13 on its consolidated financial statements.
Note 5. Earnings Per Share Applicable to Common Stockholders
The following table sets forth the computations of earnings per share amounts applicable to common stockholders for the three and six months ended June 30, 2021 and June 30, 2020:

| Three Months Ended June 30, |  | Six Months Ended June 30,
(In thousands, except per share data) | 2021 |  | 2020 |  | 2021 |  | 2020
Net loss | $ | (5,566) |  |  | $ | (3,711) |  |  | $ | (12,947) |  |  | $ | (9,613) |
Basic and diluted loss per common share | $ | (0.08) |  |  | $ | (0.06) |  |  | $ | (0.20) |  |  | $ | (0.16) |
Basic and diluted weighted average common shares outstanding (1): | 67,986 |  |  | 60,906 |  |  | 66,086 |  |  | 60,344 |
Potentially dilutive securities (2): |  |  |  |  |  |  |
Stock options | 10,535 |  |  | 11,457 |  |  | 10,535 |  |  | 11,457 |
Restricted stock units | 92 |  |  | — |  |  | 92 |  |  | — |

(1) Includes approximately 0.2 million and 0.2 million nonvested shares of restricted stock for the periods ending June 30, 2021 and June 30, 2020, respectively, which are participating securities that feature voting and dividend rights.
(2) Excluded from the computation of loss per share as their impact is antidilutive.
Note 6. Related Party Transactions
The sale of consumer products to related parties during the periods indicated are as follows:

| Net Sales |  | Trade Receivable as of
| Three Months Ended June 30, |  | Six Months Ended June 30, |  | June 30, |  | December 31,
| 2021 |  | 2020 |  | 2021 |  | 2020 |  | 2021 |  | 2020
A.S. Watson Group* | $2.9 | million |  | $1.3 | million |  | $4.5 | million |  | $3.1 | million |  | $2.2 | million |  | $0.9 | million
Horizon Ventures(1) | — |  |  | $1.6 | million |  | — |  |  | $1.6 | million |  | — |  |  | — |
Total | $2.9 | million |  | $2.9 | million |  | $4.5 | million |  | $4.7 | million |  | $2.2 | million |  | $0.9 | million

*A.S. Watson Group and Horizon Ventures are related parties through common ownership of an enterprise that beneficially owns more than 10% of the common stock of the Company.
(1) During the second quarter of 2020, Horizon Ventures made purchases to donate to the healthcare workers in Hong Kong hospitals. Horizon Ventures had insignificant sales during the second quarter of 2021.
11

Table of Contents
Note 7. Inventories
The Company's major classes of inventory and corresponding balances as of June 30, 2021 and December 31, 2020 are as follows:

(In thousands) |  | Jun 30, 2021 |  | Dec 31, 2020
Consumer Products - Finished Goods |  | $ | 4,259 |  |  | $ | 2,358 |
Consumer Products - Work in Process |  | 6,229 |  |  | 5,718 |
Bulk ingredients |  | 1,177 |  |  | 3,065 |
Reference standards |  | 518 |  |  | 542 |
|  | $ | 12,183 |  |  | $ | 11,683 |

Note 8. Stock Issuance
During June 2021, the Company sold an aggregate of 0.2 million shares of common stock under the ATM Facility and received proceeds of $1.9 million, net of offering costs and commissions, at an average price of $10.56 per share. For additional information related to the ATM facility transaction see Note 3, Liquidity.
On February 20, 2021, the Company entered into a Securities Purchase Agreement with EverFund (the "Financing”) pursuant to which the Company agreed to sell and issue approximately 3.8 million shares of common stock at a price of $6.50 per share. On February 23, 2021, the Company closed the Financing and received proceeds of $24.9 million, net of offering costs.
Note 9. Leases
Operating Leases
During the second quarter of 2021, the Company amended its existing lease in Los Angeles, California. In accordance with ASC 842, the amended lease agreement is considered to be modified and subject to lease modification guidance. The right-of-use ("ROU") asset and lease liability related to the agreement were remeasured based on the change in the lease conditions such as rent payment and lease terms. The fair value of the increase in related lease liability and ROU asset is estimated to be approximately $2.2 million. The amended lease now extends through March 31, 2027 and provides one option to extend for an additional five years.
As of June 30, 2021, the Company had ROU assets and corresponding operating lease liabilities of approximately $3.2 million and $3.5 million, respectively. For the three and six months ended June 30, 2021 and 2020, the components of operating lease expense are as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
(In thousands) | 2021 |  | 2020 |  | 2021 |  | 2020
Operating leases |  |  |  |  |  |  |
Operating lease expense | $ | 152 |  |  | $ | 120 |  |  | $ | 305 |  |  | $ | 240 |
Variable lease expense | 54 |  |  | 65 |  |  | 94 |  |  | 134 |
Operating lease expense | 206 |  |  | 185 |  |  | 399 |  |  | 374 |
Short-term lease rent expense | 63 |  |  | 64 |  |  | 125 |  |  | 127 |
Total expense | $ | 269 |  |  | $ | 249 |  |  | $ | 524 |  |  | $ | 501 |

| At Jun 30, 2021
Weighted-average remaining lease term (years) operating leases | 4.9
Weighted-average discount rate operating leases | 6.5 | %

12

Table of Contents
Future minimum lease payments under operating leases as of June 30, 2021 are as follows:

Year |  | (In thousands)
2021 (Remainder) |  | $ | 292 |
2022 |  | 669 |
2023 |  | 817 |
2024 |  | 836 |
2025 |  | 808 |
2026 |  | 564 |
Thereafter |  | 144 |
Total |  | 4,130 |
Less present value discount |  | (646) |
Present value of total operating lease liabilities |  | 3,484 |
Less current portion |  | (467) |
Long-term obligations under operating leases |  | $ | 3,017 |

Note 10. Share-Based Compensation
Equity Plans
The Company grants awards to recipients through the 2017 Equity Incentive Plan, as amended (the “2017 Plan”), which was approved by stockholders and the Board of Directors. The 2017 Plan provided for the issuance of shares that total no more than the sum of (i) 14,500,000 new shares, (ii) approximately 384,000 unallocated shares remaining available for the grant of new awards under the Second Amended and Restated 2007 Equity Incentive Plan, (iii) any returning shares such as forfeited, cancelled, or expired shares and (iv) 500,000 shares pursuant to an inducement award. The number of shares available to be issued under the 2017 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) 1.5 shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). As of June 30, 2021, there were approximately 5.1 million remaining shares available for issuance under this plan. Options expire 10 years from the date of grant.
General Vesting Conditions
The stock option and restricted stock unit awards are generally subject to a one-year cliff vesting period after which 1/3 of the shares vest with the remaining shares vesting ratably over a two-year period subject to the passage of time. Additionally, certain stock option awards are market or performance based and vest based on certain triggering events established by the Compensation Committee.
The fair value of the Company’s stock options that are not market based are estimated at the grant date using the Black-Scholes option pricing model. The Company used the following weighted average assumptions for options granted during the six months ended June 30, 2021:

Weighted Average: |  | Six Months Ended June 30, 2021
Expected term |  | 5.8 years
Expected volatility |  | 74.2 | %
Risk-free rate |  | 1.0 | %
Expected dividends |  | — | %

13

Table of Contents
Service Period Based Stock Options
The following table summarizes activity of service period-based stock options at June 30, 2021 and changes during the six months ended:

|  |  | Weighted Average |  |  |
(In thousands except per-share data and remaining contractual term) | Number of Options |  | Exercise Price |  | Remaining Contractual Term (Years) |  |  |  | Aggregate Intrinsic Value |
Outstanding at December 31, 2020 | 10,833 |  |  | $ | 3.96 |  |  | 6.8 |  |  |  |  |
Options Granted | 1,172 |  |  | 9.64 |  |  |  |  |  |  |  |
Options Exercised | (2,029) |  |  | 4.36 |  |  |  |  |  |  | $ | 12,838 |  |
Options Forfeited | (482) |  |  | 4.42 |  |  |  |  |  |  |  |
Outstanding at June 30, 2021 | 9,494 |  |  | $ | 4.55 |  |  | 6.9 |  |  |  | $ | 51,253 |  | *
Exercisable at June 30, 2021 | 6,041 |  |  | $ | 3.66 |  |  | 5.6 |  |  |  | $ | 37,427 |  | *

*The aggregate intrinsic values in the table above are based on the Company’s stock price of $9.86, which is the closing price of the Company’s stock on the last day of business for the period ended June 30, 2021.
Performance Based Stock Options
The Company also grants stock option awards that are performance based and vest based on the achievement of certain criteria established from time to time by the Compensation Committee. If these performance criteria are not met, the compensation expenses are not recognized and the expenses that have been recognized will be reversed.
The following table summarizes performance based stock options activity at June 30, 2021 and changes during the six months ended:

|  |  | Weighted Average |  |  |
(In thousands except per share data and remaining contractual term) | Number of Options |  | Exercise Price |  | Remaining Contractual Term (Years) |  |  |  | Aggregate Intrinsic Value |
Outstanding at December 31, 2020 | 81 |  |  | $ | 4.34 |  |  | 3.1 |  |  |  |  |
Options Granted | — |  |  | — |  |  |  |  |  |  |  |
Options Exercised | (40) |  |  | 4.34 |  |  |  |  |  |  | $ | 401 |  |
Options Forfeited | — |  |  | — |  |  |  |  |  |  |  |
Outstanding at June 30, 2021 | 41 |  |  | $ | 4.34 |  |  | 2.6 |  |  |  | $ | 226 |  | *
Exercisable at June 30, 2021 | 41 |  |  | $ | 4.34 |  |  | 2.6 |  |  |  | $ | 226 |  | *

*The aggregate intrinsic values in the table above are based on the Company’s stock price of $9.86, which is the closing price of the Company’s stock on the last day of business for the period ended June 30, 2021.
Total Remaining Unamortized Compensation for Stock Options
As of June 30, 2021, there was approximately $11.5 million of total unrecognized compensation expense related to non-vested stock options granted under the plans. That cost is expected to be recognized over a weighted average period of 2.1 years.
14

Table of Contents
Restricted Stock Units
Restricted stock unit awards are generally subject to a one-year cliff vesting period after which 1/3 of the shares vest with the remaining shares vesting ratably over a two-year period subject to the passage of time. The following table summarizes activity of restricted stock unit awards granted at June 30, 2021 and changes during the six months ended:

(In thousands except per share fair value) | Number of RSUs |  | Weighted Average Fair Value
Unvested shares at December 31, 2020 | — |  |  | $ | — |
Granted | 92 |  |  | 11.83 |
Vested | — |  |  | — |
Forfeited | — |  |  | — |
Unvested shares at June 30, 2021 | 92 |  |  | $ | 11.83 |
Expected to vest at June 30, 2021 | 92 |  |  | $ | 11.83 |

Total Share-Based Compensation
Total share-based compensation expense was as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
(In thousands) | 2021 |  | 2020 |  | 2021 |  | 2020
Share-based compensation expense |  |  |  |  |  |  |
Cost of sales | $ | 58 |  |  | $ | 42 |  |  | $ | 98 |  |  | $ | 75 |
Sales and marketing | 454 |  |  | 242 |  |  | 842 |  |  | 474 |
Research and development | 220 |  |  | 134 |  |  | 358 |  |  | 272 |
General and administrative | 884 |  |  | 1,293 |  |  | 1,602 |  |  | 2,763 |
Total | $ | 1,616 |  |  | $ | 1,711 |  |  | $ | 2,900 |  |  | $ | 3,584 |

Note 11. Business Segments
The Company has the following three reportable segments:
•Consumer products segment: provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers as well as to distributors.
•Ingredients segment: develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
•Analytical reference standards and services segment: includes supply of phytochemical reference standards and other research and development services.
The “Corporate and other” classification includes corporate items not allocated by the Company to each reportable segment. Additionally, there are no intersegment sales that require elimination. The Company’s three reportable segments are significant operating segments that offer differentiated services. The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.
15

Table of Contents
The following tables set forth financial information for the segments:

Three months ended June 30, 2021 |  | Consumer Products segment |  | Ingredients segment |  | Analytical Reference Standards and Services segment |  | Corporate and other |  | Total
(In thousands) |  |  |  |  |
Net sales |  | $ | 15,396 |  |  | $ | 1,504 |  |  | $ | 799 |  |  | $ | — |  |  | $ | 17,699 |
Cost of sales |  | 5,547 |  |  | 675 |  |  | 667 |  |  | — |  |  | 6,889 |
Gross profit |  | 9,849 |  |  | 829 |  |  | 132 |  |  | — |  |  | 10,810 |
Operating expenses: |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 6,190 |  |  | 1 |  |  | 41 |  |  | — |  |  | 6,232 |
Research and development |  | 926 |  |  | 78 |  |  | — |  |  | — |  |  | 1,004 |
General and administrative |  | — |  |  | — |  |  | — |  |  | 9,128 |  |  | 9,128 |
Operating expenses |  | 7,116 |  |  | 79 |  |  | 41 |  |  | 9,128 |  |  | 16,364 |
Operating income (loss) |  | $ | 2,733 |  |  | $ | 750 |  |  | $ | 91 |  |  | $ | (9,128) |  |  | $ | (5,554) |

Three months ended June 30, 2020 |  | Consumer Products segment |  | Ingredients segment |  | Analytical Reference Standards and Services segment |  | Corporate and other |  | Total
(In thousands) |  |  |  |  |
Net sales |  | $ | 11,720 |  |  | $ | 2,850 |  |  | $ | 717 |  |  | $ | — |  |  | $ | 15,287 |
Cost of sales |  | 4,339 |  |  | 1,135 |  |  | 725 |  |  | — |  |  | 6,199 |
Gross profit |  | 7,381 |  |  | 1,715 |  |  | (8) |  |  | — |  |  | 9,088 |
Operating expenses: |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 4,743 |  |  | 76 |  |  | 140 |  |  | — |  |  | 4,959 |
Research and development |  | 765 |  |  | 130 |  |  | — |  |  | — |  |  | 895 |
General and administrative |  | — |  |  | — |  |  | — |  |  | 6,921 |  |  | 6,921 |
Operating expenses |  | 5,508 |  |  | 206 |  |  | 140 |  |  | 6,921 |  |  | 12,775 |
Operating income (loss) |  | $ | 1,873 |  |  | $ | 1,509 |  |  | $ | (148) |  |  | $ | (6,921) |  |  | $ | (3,687) |

Six Months Ended June 30, 2021 |  | Consumer Products segment |  | Ingredients segment |  | Analytical Reference Standards and Services segment |  | Corporate and other |  | Total
(In thousands) |  |  |  |  |
Net sales |  | $ | 27,833 |  |  | $ | 2,819 |  |  | $ | 1,730 |  |  | $ | — |  |  | $ | 32,382 |
Cost of sales |  | 9,750 |  |  | 1,238 |  |  | 1,350 |  |  | — |  |  | 12,338 |
Gross profit |  | 18,083 |  |  | 1,581 |  |  | 380 |  |  | — |  |  | 20,044 |
Operating expenses: |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 12,301 |  |  | 11 |  |  | 178 |  |  | — |  |  | 12,490 |
Research and development |  | 1,644 |  |  | 147 |  |  | — |  |  | — |  |  | 1,791 |
General and administrative |  | — |  |  | — |  |  | — |  |  | 18,679 |  |  | 18,679 |
Operating expenses |  | 13,945 |  |  | 158 |  |  | 178 |  |  | 18,679 |  |  | 32,960 |
Operating income (loss) |  | $ | 4,138 |  |  | $ | 1,423 |  |  | $ | 202 |  |  | $ | (18,679) |  |  | $ | (12,916) |

16

Table of Contents

Six Months Ended June 30, 2020 |  | Consumer Products segment |  | Ingredients segment |  | Analytical Reference Standards and Services segment |  | Corporate and other |  | Total
(In thousands) |  |  |  |  |
Net sales |  | $ | 22,864 |  |  | $ | 5,325 |  |  | $ | 1,443 |  |  | $ | — |  |  | $ | 29,632 |
Cost of sales |  | 8,641 |  |  | 2,191 |  |  | 1,401 |  |  | — |  |  | 12,233 |
Gross profit |  | 14,223 |  |  | 3,134 |  |  | 42 |  |  | — |  |  | 17,399 |
Operating expenses: |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 9,152 |  |  | (8) |  |  | 262 |  |  | — |  |  | 9,406 |
Research and development |  | 1,453 |  |  | 251 |  |  | — |  |  | — |  |  | 1,704 |
General and administrative |  | — |  |  | — |  |  | — |  |  | 15,866 |  |  | 15,866 |
Operating expenses |  | 10,605 |  |  | 243 |  |  | 262 |  |  | 15,866 |  |  | 26,976 |
Operating income (loss) |  | $ | 3,618 |  |  | $ | 2,891 |  |  | $ | (220) |  |  | $ | (15,866) |  |  | $ | (9,577) |

At June 30, 2021 |  | Consumer Products segment |  | Ingredients segment |  | Analytical Reference Standards and Services segment |  | Corporate and other |  | Total
(In thousands) |  |  |  |  |
Total assets |  | $ | 16,510 |  |  | $ | 2,216 |  |  | $ | 832 |  |  | $ | 46,284 |  |  | $ | 65,842 |

At December 31, 2020 |  | Consumer Products segment |  | Ingredients segment |  | Analytical Reference Standards and Services segment |  | Corporate and other |  | Total
(In thousands) |  |  |  |  |
Total assets |  | $ | 11,567 |  |  | $ | 3,701 |  |  | $ | 802 |  |  | $ | 22,288 |  |  | $ | 38,358 |

Disaggregation of Revenue
The Company disaggregates its revenue from contracts with customers by type of goods or services for each of its segments, as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. See details in the tables below.

Three Months Ended June 30, 2021 |  | Consumer Products Segment |  | Ingredients Segment |  | Analytical Reference Standards and Services Segment |  | Total
(In thousands) |  |  |  |
TRU NIAGEN , Consumer Product |  | $ | 15,396 |  |  | $ | — |  |  | $ | — |  |  | $ | 15,396 |
NIAGEN Ingredient |  | — |  |  | 1,281 |  |  | — |  |  | 1,281 |
Subtotal NIAGEN Related |  | $ | 15,396 |  |  | $ | 1,281 |  |  | $ | — |  |  | $ | 16,677 |
Other Ingredients |  | — |  |  | 223 |  |  | — |  |  | 223 |
Reference Standards |  | — |  |  | — |  |  | 695 |  |  | 695 |
Consulting and Other |  | — |  |  | — |  |  | 104 |  |  | 104 |
Subtotal Other Goods and Services |  | $ | — |  |  | $ | 223 |  |  | $ | 799 |  |  | $ | 1,022 |
Total Net Sales |  | $ | 15,396 |  |  | $ | 1,504 |  |  | $ | 799 |  |  | $ | 17,699 |

17

Table of Contents

Three Months Ended June 30, 2020 |  | Consumer Products Segment |  | Ingredients Segment |  | Analytical Reference Standards and Services Segment |  | Total
(In thousands) |  |  |  |
TRU NIAGEN , Consumer Product |  | $ | 11,720 |  |  | $ | — |  |  | $ | — |  |  | $ | 11,720 |
NIAGEN Ingredient |  | — |  |  | 1,995 |  |  | — |  |  | 1,995 |
Subtotal NIAGEN Related |  | $ | 11,720 |  |  | $ | 1,995 |  |  | $ | — |  |  | $ | 13,715 |
Other Ingredients |  | — |  |  | 855 |  |  | — |  |  | 855 |
Reference Standards |  | — |  |  | — |  |  | 686 |  |  | 686 |
Consulting and Other |  | — |  |  | — |  |  | 31 |  |  | 31 |
Subtotal Other Goods and Services |  | $ | — |  |  | $ | 855 |  |  | $ | 717 |  |  | $ | 1,572 |
Total Net Sales |  | $ | 11,720 |  |  | $ | 2,850 |  |  | $ | 717 |  |  | $ | 15,287 |

Six Months Ended June 30, 2021 |  | Consumer Products Segment |  | Ingredients Segment |  | Analytical Reference Standards and Services Segment |  | Total
(In thousands) |  |  |  |
TRU NIAGEN , Consumer Product |  | $ | 27,833 |  |  | $ | — |  |  | $ | — |  |  | $ | 27,833 |
NIAGEN Ingredient |  | — |  |  | 2,484 |  |  | — |  |  | 2,484 |
Subtotal NIAGEN Related |  | $ | 27,833 |  |  | $ | 2,484 |  |  | $ | — |  |  | $ | 30,317 |
Other Ingredients |  | — |  |  | 335 |  |  | — |  |  | 335 |
Reference Standards |  | — |  |  | — |  |  | 1,495 |  |  | 1,495 |
Consulting and Other |  | — |  |  | — |  |  | 235 |  |  | 235 |
Subtotal Other Goods and Services |  | $ | — |  |  | $ | 335 |  |  | $ | 1,730 |  |  | $ | 2,065 |
Total Net Sales |  | $ | 27,833 |  |  | $ | 2,819 |  |  | $ | 1,730 |  |  | $ | 32,382 |

Six Months Ended June 30, 2020 |  | Consumer Products Segment |  | Ingredients Segment |  | Analytical Reference Standards and Services Segment |  | Total
(In thousands) |  |  |  |
TRU NIAGEN , Consumer Product |  | $ | 22,864 |  |  | $ | — |  |  | $ | — |  |  | $ | 22,864 |
NIAGEN Ingredient |  | — |  |  | 3,956 |  |  | — |  |  | 3,956 |
Subtotal NIAGEN Related |  | $ | 22,864 |  |  | $ | 3,956 |  |  | $ | — |  |  | $ | 26,820 |
Other Ingredients |  | — |  |  | 1,369 |  |  | — |  |  | 1,369 |
Reference Standards |  | — |  |  | — |  |  | 1,359 |  |  | 1,359 |
Consulting and Other |  | — |  |  | — |  |  | 84 |  |  | 84 |
Subtotal Other Goods and Services |  | $ | — |  |  | $ | 1,369 |  |  | $ | 1,443 |  |  | $ | 2,812 |
Total Net Sales |  | $ | 22,864 |  |  | $ | 5,325 |  |  | $ | 1,443 |  |  | $ | 29,632 |

18

Table of Contents
Disclosure of Major Customers
Major customers who accounted for more than 10% of the Company’s total sales were as follows:

|  | Three Months Ended June 30, |  | Six Months Ended June 30,
Major Customers |  | 2021 |  | 2020 |  | 2021 |  | 2020
A.S. Watson Group - Related Party |  | 16.5 | % |  | * |  | 13.8 | % |  | 10.6 | %
Horizon Ventures - Related Party(1) |  | * |  | 10.2 | % |  | * |  | *

* Represents less than 10%.
(1) During the second quarter of 2020, Horizon Ventures made purchases to donate to the healthcare workers in Hong Kong hospitals.
Major accounts which had more than 10% of the Company’s total trade receivables were as follows:

|  | Percentage of the Company's Total Trade Receivables
Major Customers |  | At June 30, 2021 |  | At December 31, 2020
A.S. Watson Group - Related Party |  | 37.5 | % |  | 31.9 | %
Walmart™ (1) |  | 17.1 | % |  | *
Matakana Health |  | 11.5 | % |  | 11.1 | %
Life Extension |  | * |  | 17.7 | %
Amazon Marketplaces |  | * |  | 12.0 | %

* Represents less than 10%.
(1) The Company began retail distribution of Tru Niagen® in Walmart™ stores across the United States beginning in June 2021.
Note 12. Commitments and Contingencies
Legal proceedings
1. Elysium Health, LLC
(A) California Action
On December 29, 2016, ChromaDex, Inc. filed a complaint in the United States District Court for the Central District of California, naming Elysium Health, Inc. (together with Elysium Health, LLC, “Elysium”) as defendant (the “Complaint”). On January 25, 2017, Elysium filed an answer and counterclaims in response to the Complaint (together with the Complaint, the “California Action”). Over the course of the California Action, the parties have each filed amended pleadings several times and have each engaged in several rounds of motions to dismiss and one round of motion for judgment on the pleadings with respect to various claims. Most recently, on November 27, 2018, ChromaDex, Inc. filed a fifth amended complaint that added an individual, Mark Morris, as a defendant. Elysium and Morris (“the Defendants”) moved to dismiss on December 21, 2018. The court denied Defendants’ motion on February 4, 2019. Defendants filed their answer to ChromaDex, Inc.’s fifth amended complaint on February 19, 2019. ChromaDex, Inc. filed an answer to Elysium’s restated counterclaims on March 5, 2019. Discovery closed on August 9, 2019.
19

Table of Contents
On August 16, 2019, the parties filed motions for partial summary judgment as to certain claims and counterclaims. The parties filed opposition briefs on August 28, 2019, and reply briefs on September 4, 2019. On October 9, 2019, among other things, the court vacated the previously scheduled trial date, ordered supplemental briefing with respect to certain issues related to summary judgment. Elysium filed its opening supplemental brief on October 30, 2019, ChromaDex filed its opening supplemental brief on November 18, 2019, and Elysium filed a reply brief on November 27, 2019, and the court heard argument on January 13, 2020. On January 16, 2020, the court granted both parties’ motions for summary judgment in part and denied both in part. On ChromaDex’s motion, the court granted summary judgment in favor of ChromaDex on Elysium’s counterclaims for (i) breach of contract related to manufacturing NIAGEN® according to the defined standard, selling NIAGEN and ingredients that are substantially similar to pterostilbene to other customers, distributing the NIAGEN® product specifications, and failing to provide information concerning the quality and identity of NIAGEN®, and (ii) breach of the implied covenant of good faith and fair dealing. The court denied summary judgment on Elysium’s counterclaims for (i) fraudulent inducement of the Trademark License and Royalty Agreement, dated February 3, 2014, by and between ChromaDex, Inc. and Elysium (the “License Agreement”), (ii) patent misuse, and (iii) unjust enrichment. On Elysium’s motion, the court granted summary judgment in favor of Elysium on ChromaDex’s claim for damages related to $110,000 in avoided costs arising from documents that Elysium used in violation of the Supply Agreement, dated February 3, 2014, by and between ChromaDex, Inc. and Elysium, as amended (the “NIAGEN® Supply Agreement”). The court denied summary judgment on Elysium’s counterclaim for breach of contract related to certain refunds or credits to Elysium. The court also denied summary judgment on ChromaDex’s breach of contract claim against Morris and claims for disgorgement of $8.3 million in Elysium’s resale profits, $600,000 for a price discount received by Elysium, and $684,781 in Morris’s compensation.
Following the court’s January 16, 2020 order, the claims that ChromaDex, Inc. presently asserts in the California Action, among other allegations, are that (i) Elysium breached the Supply Agreement, dated June 26, 2014, by and between ChromaDex, Inc. and Elysium (the “pTeroPure® Supply Agreement”), by failing to make payments to ChromaDex, Inc. for purchases of pTeroPure® and by improper disclosure of confidential ChromaDex, Inc. information pursuant to the pTeroPure® Supply Agreement, (ii) Elysium breached the NIAGEN® Supply Agreement, by failing to make payments to ChromaDex, Inc. for purchases of NIAGEN®, (iii) Defendants willfully and maliciously misappropriated ChromaDex, Inc. trade secrets concerning its ingredient sales business under both the California Uniform Trade Secrets Act and the Federal Defend Trade Secrets Act, (iv) Morris breached two confidentiality agreements he signed by improperly stealing confidential ChromaDex, Inc. documents and information, (v) Morris breached his fiduciary duty to ChromaDex, Inc. by lying to and competing with ChromaDex, Inc. while still employed there, and (vi) Elysium aided and abetted Morris’s breach of fiduciary duty. ChromaDex, Inc. is seeking damages and interest for Elysium’s alleged breaches of the NIAGEN® Supply Agreement and pTeroPure® Supply Agreement and Morris’s alleged breaches of his confidentiality agreements, compensatory damages and interest, punitive damages, injunctive relief, and attorney’s fees for Defendants’ alleged willful and malicious misappropriation of ChromaDex, Inc.’s trade secrets, and compensatory damages and interest, disgorgement of all benefits received, and punitive damages for Morris’s alleged breach of his fiduciary duty and Elysium’s aiding and abetting of that alleged breach.
The claims that Elysium presently alleges in the California Action are that (i) ChromaDex, Inc. breached the NIAGEN® Supply Agreement by not issuing certain refunds or credits to Elysium, (ii) ChromaDex, Inc. fraudulently induced Elysium into entering into the License Agreement, (iv) ChromaDex, Inc.’s conduct constitutes misuse of its patent rights, and (v) ChromaDex, Inc. was unjustly enriched by the royalties Elysium paid pursuant to the License Agreement. Elysium is seeking damages for ChromaDex, Inc.’s alleged breaches of the NIAGEN® Supply Agreement, and compensatory damages, punitive damages, and/or rescission of the License Agreement and restitution of any royalty payments conveyed by Elysium pursuant to the License Agreement, and a declaratory judgment that ChromaDex, Inc. has engaged in patent misuse.
On January 17, 2020, Elysium moved to substitute its counsel. The same day, the court ordered hearing on that motion for January 21, 2020, and granted Elysium’s motion at the hearing. On January 23, 2020, the court issued a scheduling order that, among other things, set trial on the remaining claims to begin on May 12, 2020. On March 19, 2020, in light of the global 2019 coronavirus disease ("COVID-19" or "COVID") pandemic and ongoing private mediation efforts, the parties jointly stipulated to adjourn the trial date. The court vacated the trial date on March 20, 2020. The court held a telephonic status conference on June 9, 2020, during which the court indicated that it will reschedule the jury trial as soon as conditions permit. On November 4, 2020, the parties submitted a joint status report indicating that they will propose a new trial date as soon as the court announces that it will resume jury trials. On November 18, 2020, the court set trial to begin on September 21, 2021.
20

Table of Contents
On December 11, 2020, Elysium filed a “Notice of Correction of Depositions” related to the depositions of its chief executive officer, Eric Marcotulli, and chief operating officer, Daniel Alminana, both taken in March 2019. On March 8, 2021, based in part on information that Elysium submitted under seal with that notice, ChromaDex, Inc. filed a motion for sanctions or, in the alternative, reconsideration of the court’s January 16, 2020 order regarding summary judgment, in which ChromaDex, Inc. moved to dismiss Elysium’s third, fourth, and fifth counterclaims. Elysium’s opposition brief was filed on March 22, 2021. ChromaDex, Inc. filed its reply brief on March 29, 2021. On April 27, 2021, the court denied ChromaDex, Inc’s motion for terminating sanctions, but concluded that the evidence at issue in the motion will be admissible at trial.
(B) Southern District of New York Action
On September 27, 2017, Elysium Health Inc. (“Elysium Health”) filed a complaint in the United States District Court for the Southern District of New York, against ChromaDex, Inc. (the “Elysium SDNY Complaint”). Elysium Health alleged in the Elysium SDNY Complaint that ChromaDex, Inc. made false and misleading statements in a citizen petition to the Food and Drug Administration it filed on or about August 18, 2017. Among other allegations, Elysium Health averred that the citizen petition made Elysium Health’s product appear dangerous, while casting ChromaDex, Inc.’s own product as safe. The Elysium SDNY Complaint asserted four claims for relief: (i) false advertising under the Lanham Act, 15 U.S.C. § 1125(a); (ii) trade libel; (iii) deceptive business practices under New York General Business Law § 349; and (iv) tortious interference with prospective economic relations. On October 26, 2017, ChromaDex, Inc. moved to dismiss the Elysium SDNY Complaint on the grounds that, inter alia, its statements in the citizen petition are immune from liability under the Noerr-Pennington Doctrine, the litigation privilege, and New York’s Anti-SLAPP statute, and that the Elysium SDNY Complaint failed to state a claim. Elysium Health opposed the motion on November 2, 2017. ChromaDex, Inc. filed its reply on November 9, 2017.
On October 26, 2017, ChromaDex, Inc. filed a complaint in the United States District Court for the Southern District of New York against Elysium Health (the “ChromaDex SDNY Complaint”). ChromaDex, Inc. alleges that Elysium Health made material false and misleading statements to consumers in the promotion, marketing, and sale of its health supplement product, Basis, and asserts five claims for relief: (i) false advertising under the Lanham Act, 15 U.S.C. §1125(a); (ii) unfair competition under 15 U.S.C. § 1125(a); (iii) deceptive practices under New York General Business Law § 349; (iv) deceptive practices under New York General Business Law § 350; and (v) tortious interference with prospective economic advantage. On November 16, 2017, Elysium Health moved to dismiss for failure to state a claim. ChromaDex, Inc. opposed the motion on November 30, 2017 and Elysium Health filed a reply on December 7, 2017.
On November 3, 2017, the Court consolidated the Elysium SDNY Complaint and the ChromaDex SDNY Complaint actions under the caption In re Elysium Health-ChromaDex Litigation, 17-cv-7394, and stayed discovery in the consolidated action pending a Court-ordered mediation. The mediation was unsuccessful. On September 27, 2018, the Court issued a combined ruling on both parties’ motions to dismiss. For ChromaDex’s motion to dismiss, the Court converted the part of the motion on the issue of whether the citizen petition is immune under the Noerr-Pennington Doctrine into a motion for summary judgment, and requested supplemental evidence from both parties, which were submitted on October 29, 2018. The Court otherwise denied the motion to dismiss. On January 3, 2019, the Court granted ChromaDex, Inc.’s motion for summary judgment under the Noerr-Pennington Doctrine and dismissed all claims in the Elysium SDNY Complaint. Elysium moved for reconsideration on January 17, 2019. The Court denied Elysium’s motion for reconsideration on February 6, 2019, and issued an amended final order granting ChromaDex, Inc.’s motion for summary judgment on February 7, 2019.
The Court granted in part and denied in part Elysium’s motion to dismiss, sustaining three grounds for ChromaDex’s Lanham Act claims while dismissing two others, sustaining the claim under New York General Business Law § 349, and dismissing the claims under New York General Business Law § 350 and for tortious interference. Elysium filed an answer and counterclaims on October 10, 2018, alleging claims for (i) false advertising under the Lanham Act, 15 U.S.C. §1125(a); (ii) unfair competition under 15 U.S.C. § 1125(a); and (iii) deceptive practices under New York General Business Law § 349. ChromaDex answered Elysium’s counterclaims on November 2, 2018.
ChromaDex, Inc. filed an amended complaint on March 27, 2019, adding new claims against Elysium Health for false advertising and unfair competition under the Lanham Act, 15 U.S.C. § 1125(a). On April 10, 2019, Elysium Health answered the amended complaint and filed amended counterclaims, also adding new claims against ChromaDex, Inc. for false advertising and unfair competition under the Lanham Act, 15 U.S.C. § 1125(a). On July 1, 2019, Elysium Health filed further amended counterclaims, adding new claims under the Copyright Act §§ 106 & 501. On February 9, 2020, ChromaDex, Inc. filed a motion for leave to amend its complaint to add additional claims against Elysium Health for false advertising and unfair competition. On February 10, 2020, Elysium Health filed a motion for leave to amend its counterclaims to identify allegedly false and misleading statements in ChromaDex’s advertising. Those motions were both granted after respective stipulations. On March 12, 2020, Elysium Health answered the second amended complaint. On March 13, 2020, ChromaDex, Inc. filed an answer and objection to Elysium Health’s third amended counterclaims.
21

Table of Contents
On December 14, 2020, Elysium Health filed a motion to supplement and amend its counterclaims to add claims regarding alleged advertising related to COVID, to add an allegation about a change to the ChromaDex website, and to remove its copyright infringement claim under the Copyright Act. On January 19, 2021, the Court denied Elysium Health’s motion to add claims regarding alleged advertising related to COVID. The Court granted the unopposed requests to add an allegation about a change to ChromaDex’s website and to remove Elysium’s Copyright Act claim. Pursuant to the Court’s order, Elysium filed fourth amended counterclaims on April 21, 2021.
All discovery closed on April 23, 2021. The Court vacated a previously scheduled joint pretrial order and trial date because of COVID-19, and the Court has informed the Parties that trial will be rescheduled for November or December 2021.
Both parties filed dispositive and Daubert motions on June 4, 2021. Opposition papers were filed by both parties on June 25, 2021, and reply papers were filed on July 9, 2021.
The Company is unable to predict the outcome of these matters and, at this time, cannot reasonably estimate the possible loss or range of loss with respect to the legal proceedings discussed herein. As of June 30, 2021, ChromaDex, Inc. did not accrue a potential loss for the California Action or the Elysium SDNY Complaint because ChromaDex, Inc. believes that the allegations are without merit and thus it is not probable that a liability has been incurred.
(C) Delaware - Patent Infringement Action
On September 17, 2018, ChromaDex, Inc. and Trustees of Dartmouth College filed a patent infringement complaint in the United States District Court for the District of Delaware against Elysium Health, Inc. The complaint alleges that Elysium’s BASIS® dietary supplement infringes U.S. Patent Nos. 8,197,807 (“‘807 Patent”) and 8,383,086 (“‘086 Patent”) that comprise compositions containing isolated nicotinamide riboside held by Dartmouth and licensed exclusively to ChromaDex, Inc. On October 23, 2018, Elysium filed an answer to the complaint. The answer asserts various affirmative defenses and denies that Plaintiffs are entitled to any relief.
On November 7, 2018, Elysium filed a motion to stay the patent infringement proceedings pending resolution of (1)the inter partes review of the ‘807 Patent and the ‘086 Patent before the Patent Trial and Appeal Board (“PTAB”) and (2)the outcome of the litigation in the California Action. ChromaDex, Inc. filed an opposition brief on November 21, 2018 detailing the issues with Elysium’s motion to stay. In particular, ChromaDex, Inc. argued that given claim 2 of the ‘086 Patent was only included in the PTAB’s inter partes review for procedural reasons the PTAB was unlikely to invalidate claim 2 and therefore litigation in Delaware would continue regardless. In addition, ChromaDex, Inc. argued that the litigation in the California Action is unlikely to have a significant effect on the ongoing patent litigation. After the PTAB released its written decision upholding claim 2 of the ‘086 Patent, proving right ChromaDex, Inc.’s prediction, ChromaDex, Inc. informed the Delaware court of the PTAB’s decision on January 17, 2019. On June 19, 2019, the Delaware court granted in part and denied in part Elysium’s motion, ordering that the case was stayed pending the resolution of Elysium’s patent misuse counterclaim in the California Action.
On November 1, 2019, ChromaDex, Inc. filed a motion to lift the stay due to changed circumstances in the California Action, among other reasons. Briefing on the motion was completed on November 22, 2019. On January 6, 2020, the Delaware court issued an oral order instructing the parties to submit a joint status report after the January 13, 2020 motions hearing in the California Action. The joint status report was submitted on January 30, 2020. On February 4, 2020, the Delaware court issued an order granting ChromaDex, Inc.’s motion to lift the stay and setting a scheduling conference for March 10, 2020. On March 19, 2020, the Delaware court entered a scheduling order, which, among other things, set the claim-construction hearing for December 17, 2020 and trial for the week of September 27, 2021. On April 17, 2020, ChromaDex, Inc. served infringement contentions. Elysium filed a Second Amended Answer on July 10, 2020.
On April 24, 2020, ChromaDex, Inc. moved for leave to amend the complaint to add Healthspan Research, LLC as a plaintiff. On May 5, 2020, Elysium filed its opposition to ChromaDex, Inc.’s motion for leave to amend and moved to dismiss ChromaDex, Inc. for alleged lack of standing. ChromaDex, Inc. filed its opposition to Elysium’s motion to dismiss and reply in support of its motion to amend on May 19, 2020. Elysium filed its reply in support of its motion to dismiss on May 26, 2020. The Court held a hearing on the motion for leave to amend the complaint and Elysium’s motion to dismiss on September 16, 2020. On December 15, 2020, the Court entered orders (i) granting in part and denying in part Elysium’s motion to dismiss ChromaDex, Inc. for alleged lack of standing; and (ii) denying ChromaDex, Inc.’s motion for leave to amend. ChromaDex, Inc. filed a motion for reargument on December 29, 2020. Elysium filed a response to the motion for reargument on January 28, 2021. ChromaDex, Inc. filed a motion for leave to file a reply on February 8, 2021. Elysium filed a response to the motion for leave to file a reply on February 12, 2021. ChromaDex, Inc. filed a reply to the motion for leave to file a reply on February 19, 2021. The Court granted the motion for leave to file the reply on April 26, 2021, and denied the motion for reargument on April 27, 2021.
22

Table of Contents
On July 22, 2020 the parties filed a Joint Claim Construction Chart and respective motions for claim construction. The parties filed a Joint Claim Construction Brief on November 5, 2020. The Court held a Markman hearing on claim-construction issues on December 17, 2020. The Court entered a claim-construction ruling on January 5, 2021.
Fact discovery closed on January 26, 2021. Opening expert reports were served on February 9, 2021. Responsive expert reports were served on March 9, 2021. Reply expert reports were served on March 30, 2021. Both parties filed dispositive and Daubert motions on April 27, 2021.
Trial is scheduled for September 27-30, 2021.
2. Thorne Research, Inc.
(A) Inter Partes Review Proceedings
On or around September 28, 2020, Thorne Research, Inc. (“Thorne”) provided notice to ChromaDex, Inc. that it intended to terminate its March 25, 2019 Supply Agreement and subsequent amendments with ChromaDex, Inc., effective as of December 31, 2020. A discussion between ChromaDex, Inc. and Thorne followed, and Thorne asserted that it could challenge the ‘086 Patent in an inter partes review (“IPR”) proceeding on the basis of prior art, but would be willing to enter into a mutual existence agreement that would permit Thorne to source NR from a third party. Thorne did not offer substantive information supporting a prior art claim or about the nature of the threatened IPR.
On December 1, 2020, Thorne filed a petition for IPR of the ‘086 Patent. Dartmouth’s preliminary response to the petition was filed on March 15, 2021. On June 10, 2021, the Patent Trial and Appeal Board (“PTAB”) issued a decision instituting an IPR on the ‘086 Patent.
On February 1, 2021, Thorne filed a petition for IPR of the ‘807 Patent. Dartmouth’s preliminary response to the petition was filed on May 18, 2021. The PTAB’s institution decision is expected to be issued by August 18, 2021.
(B) Southern District of New York – Patent Infringement Action
On May 12, 2021, ChromaDex, Inc. and Trustees of Dartmouth College filed a patent infringement complaint in the United States District Court for the Southern District of New York. The complaint alleges that certain of Thorne’s dietary supplements containing isolated NR infringe the ‘807 and ‘086 Patents, which claim compositions containing isolated nicotinamide riboside and are held by Dartmouth and licensed exclusively to ChromaDex, Inc. On July 6, 2021, Thorne filed an answer and counterclaims to the complaint. The answer asserts various affirmative defenses and denies that Plaintiffs are entitled to any relief. The counterclaims seek declaratory judgment of patent invalidity for the ‘807 and ‘086 Patents. On July 8, 2021, the parties filed a proposed stipulation and order staying the matter pending issuance of the institution decision in the ‘807 Patent IPR. On July 9, 2021, the Court granted the stipulation and order to stay.
3. Other
(A) Employee Dispute
On September 25, 2020, the Company received a demand letter from a former employee, alleging a series of employment-related claims against the Company after the employee was laid off as part of a company restructuring. The employee alleges she was harassed and, ultimately, terminated in retaliation for taking intermittent leave, under the Family and Medical Leave Act. No lawsuit has been filed to date. The Company believes these claims are without merit and is seeking to amicably resolve the matter pre-lawsuit. The Company does not anticipate that the ultimate resolution of this matter will be material to the Company’s operations, financial condition or cash flows.
23

Table of Contents
(B) Rejuvenation Therapeutics
On September 15, 2020, the Company received a letter from a customer, Rejuvenation Therapeutics Corp. (“Rejuvenation”), and has received subsequent correspondence, requesting a full refund of approximately $1.6 million of NIAGEN® it purchased, alleging breaches of the supply agreement between the parties. As of June 30, 2021, the Company has recorded a return liability of approximately $0.5 million, which the Company offered to settle in good faith. On May 13, 2021, Rejuvenation filed a complaint in the Superior Court of the State of California, County of Orange, asserting causes of action for Concealment and Negligent Misrepresentation. On July 20, 2021, Rejuvenation filed an amended complaint adding a claim for Declaratory Relief. The Company’s response to the amended complaint is due August 20, 2021. The Company believes these claims are without merit and will aggressively defend itself. The Company does not anticipate that the ultimate resolution of this matter will be material to the Company’s operations, financial condition or cash flows.
Contingencies
(A) In September 2019, the Company received a letter from a licensor stating that the Company owed the licensor $1.6 million plus interest of sublicense fees as a result of the Company entering into the supply agreement with a customer. After reviewing the relevant facts and circumstances, the Company believes that the Company does not owe any sublicense fees to the licensor and has corresponded with the licensor to resolve the matter. The Company does not believe that the ultimate resolution of this matter will be material to the Company’s results of operations, financial condition or cash flows.
(B) On November 17, 2020, the Company received a warning letter (“the Letter”) from the United States Food and Drug Administration (“FDA”) and Federal Trade Commission (“FTC”). The Letter references statements issued by the Company relating to preclinical and clinical research results involving nicotinamide riboside and COVID-19. The statements were included in press releases and referenced in social media posts.
On November 18, 2020, the Company provided a response to the Letter stating that the Company disagrees with the assertion in the Letter that the Company’s products are intended to mitigate, prevent, treat, diagnose or cure COVID-19 in violation of certain sections of the FD&C Act or that they were unsubstantiated under the FTC Act, but rather accurately reflected the state of the science and the results of scientific research. Nonetheless, the Company also responded that it had deleted social media references to the studies and removed related press releases from its website.
On April 30, 2021, the Company received an additional warning letter (the “Second Letter”) from only the FTC. The Second Letter references the original Letter, and cites additional statements issued by the Company and certain officers and advisors of the Company relating to nicotinamide riboside and scientific studies related to COVID-19. The Second Letter asserts that such statements contain coronavirus-related prevention or treatment claims and are deceptive in violation of the Federal Trade Commission Act.
On May 4, 2021, the Company provided a response to the Second Letter stating that it had removed the social posts from its accounts identified in the Second Letter and requested that third parties remove the post from their accounts that were identified in the Second Letter. The Company stated that the press release identified in the Second Letter is appropriate and not a deceptive act or practice under applicable law. The Company affirmed its belief in the need to accurately report on the scientific results of its studies to its investors, and welcomed the opportunity to discuss its R&D program with the FTC, and receive guidance on future releases.
The Company does not believe that the ultimate resolution of this matter will be material to the Company’s results of operations, financial condition or cash flows.
Subsequent Event Commitments
Effective as of August 2, 2021, the Company entered into a Seventh Amendment (the “Seventh Amendment”) to the Manufacturing and Supply Agreement (such agreement as amended, the “Grace Manufacturing Agreement”), originally effective in January 2016, with W.R. Grace & Co. –Conn. Pursuant to the Seventh Amendment, the Company is obligated to purchase approximately $18.0 million of total inventory between January 1, 2022 and December 31, 2022 and $3.5 million of inventory from January 1, 2023 through June 30, 2023. The Grace Manufacturing Agreement will expire on June 30, 2023, subject to renewal periods to be negotiated by the parties.
24

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Certain statements in this Management's Discussion and Analysis (“MD&A”), other than purely historical information, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could," "predicts," "projects," "continue," "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers should carefully review the risk factors and related notes set forth below in Part II, Item 1A, “Risk Factors” and included under Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 12, 2021 (our “Annual Report”).
The following MD&A is intended to help readers understand the results of our operation and financial condition, and is provided as a supplement to, and should be read in conjunction with, our Interim Unaudited Financial Statements and the accompanying Notes to Interim Unaudited Financial Statements under Part 1, Item 1 of this Quarterly Report on Form 10-Q.
Growth and percentage comparisons made herein generally refer to the three and six months ended June 30, 2021 compared with the three and six months ended June 30, 2020 unless otherwise noted. Unless otherwise indicated or unless the context otherwise requires, all references in this document to “we,” “us,” “our,” the “Company,” “ChromaDex” and similar expressions refer to ChromaDex Corporation, and depending on the context, its subsidiaries.
Company Overview
ChromaDex is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (“NAD+”), levels of which decline with age.
NAD+ is an essential coenzyme and a key regulator of cellular metabolism. Best known for its role in cellular energy production, NAD+ is now thought to play an important role in healthy aging. Many cellular functions related to health and healthy aging are sensitive to levels of locally available NAD+ and this represents an active area of research in the field of NAD+.
NAD+ levels are not constant, and in humans, NAD+ levels have been shown to decline by more than 50% from young adulthood to middle age. There are other causes of NAD+ depletion, such as poor diet, alcohol consumption and a number of disease states. NAD+ levels may also be increased, including through calorie restriction and moderate exercise. Healthy aging, mitochondrial health and NAD+ continue to be areas of focus in the research community. As of 2021, there were over 350 published human clinical studies related to NAD+ and its impact on health. The areas of study include understanding NAD+’s role in Alzheimer’s disease, Parkinson’s disease, neuropathy, sarcopenia, liver disease and heart failure.
In 2013, ChromaDex commercialized NIAGEN® nicotinamide riboside (“NR”), a novel form of vitamin B3. Data from numerous preclinical studies, and confirmed in human clinical trials, show that NR is a highly efficient NAD+ precursor that significantly raises blood and tissue NAD+ levels. NIAGEN® is safe for human consumption. NIAGEN® has twice been successfully reviewed under the U.S. Food and Drug Administration’s new dietary ingredient (“NDI”) notification program, has been successfully notified to the U.S. Food and Drug Administration (the “FDA”) as generally recognized as safe (“GRAS”), and has been approved by Health Canada, the European Commission and the Therapeutic Goods Administration of Australia. Clinical studies of NIAGEN® have demonstrated a variety of outcomes including increased NAD+ levels, altered body composition, increased cellular metabolism and increased energy production. NIAGEN® is the trade name for our proprietary ingredient NR, and is protected by patents to which we are the exclusive licensee.
ChromaDex is among the world leaders in the emerging NAD+ space. ChromaDex has amassed more than 225 research partnerships with leading universities and research institutions around the world including the National Institutes of Health, Cornell, Dartmouth, Harvard, Massachusetts Institute of Technology, University of Cambridge and the Mayo Clinic. Additional relationships are currently being developed.
25

Table of Contents
Our scientific advisory board is led by Chairman Dr. Roger Kornberg, Nobel Laureate Stanford Professor, Dr. Charles Brenner, one of the world’s recognized experts in NAD+ and inventor of nicotinamide riboside, Dr. Rudy Tanzi, the co-chair of the department of neurology at Harvard Medical School and one of the world’s leading experts in food and nutrition, Sir John Walker, Nobel Laureate and Emeritus Director, MRC Mitochondrial Biology Unit in the University of Cambridge, England, Dr. Bruce German, Chairman of food, nutrition and health at the University of California, Davis, Dr. Brunie Felding, Associate Professor, Department of Molecular Medicine at Scripps Research Institute, California Campus, and Dr. David Katz, the Founder and former director of Yale University’s Yale-Griffin Prevention Research Center; President and Founder of the non-profit True Health Initiative; and Founder and Chief Executive Officer of Diet ID, Inc.
Impact of COVID-19
The worldwide outbreak of the 2019 coronavirus disease ("COVID-19") continues to drive global uncertainty and disruption, which has created headwinds for our business. Despite this, our e-commerce business continues to perform relatively well in this challenging environment.
Our international retail business, including sales to A.S. Watson group and other partners in international markets, has been impacted by the effects of COVID-19, due to store closures and reduced operating hours; however, we are seeing signs of recovery. Our United States ("U.S.") retail operations are not a significant portion of our business today; however, we began distributing Tru Niagen® in 3,800+ U.S. Walmart™ stores beginning in June 2021. In general, the U.S. retail industry has recovered fairly well as the COVID-19 vaccine has been widely accessible and businesses continue to reopen and remain open.
Global supply chains continue to be impacted by COVID-19, including challenges with transportation, logistics and production lead-times, as well as labor shortages and cost inflation. In the first quarter of 2021, we experienced delays due to global packaging shortages for our consumer products across our supply chain. These have been addressed in the second quarter and we have otherwise not encountered any major disruptions in our supply chain. It is our intention to maintain adequate safety stocks to support our growth and we currently have adequate inventory on hand to meet our current demands. Overall, we believe the supply chain disruptions due to the COVID-19 pandemic will not have a material impact to our business operations.
Our primary focus throughout the COVID-19 pandemic has remained ensuring the health and safety of our employees by closing our offices or enhancing safety protocols in place to ensure the well-being of our employees. We adapted to the new environment and have been able to successfully conduct business virtually.
Financial Condition and Results of Operations
The discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of these financial statements requires making estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues, if any, and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
On February 20, 2021, the Company entered into a Securities Purchase Agreement with EverFund pursuant to which the Company agreed to sell and issue approximately 3.8 million shares of common stock at a purchase price of $6.50 per share (the “financing”). On February 23, 2021, the Company closed the Financing and received proceeds of $24.9 million, net of offering costs.
In June 2020, the Company entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR, Inc. (“B. Riley FBR”) and Raymond James & Associates, Inc. (“Raymond James” and together with B. Riley FBR, the “Sales Agents”) under which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million from time to time through the Sales Agents (the “ATM Facility”). During the three months ended June 30, 2021, we sold an aggregate of 0.2 million shares of our common stock under the ATM Facility resulting in proceeds of $1.9 million, net of offering costs and commissions. The shares sold at an average price of $10.56 per share. As of June 30, 2021, approximately $47.8 million remains available under the ATM Facility.
26

Table of Contents
As of June 30, 2021, the Company had approximately $38.8 million of cash and cash equivalents on hand. We anticipate that our current cash, cash equivalents, and available line of credit up to $7.0 million from Western Alliance Bank will be sufficient to meet our projected operating plans for at least the next twelve months. We may, however, seek additional capital in the next twelve months, both to meet our projected operating plans after the next twelve months and/or to fund our longer term strategic objectives.
Additional capital may come from other public and/or private stock or debt offerings, borrowings under lines of credit or other sources. These additional funds may not be available on favorable terms, or at all. Further, if we issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution and the new equity or debt securities we issue may have rights, preferences and privileges senior to those of our existing stockholders. In addition, if we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to our products or proprietary technologies, or to grant licenses on terms that are not favorable to us. If we cannot raise funds on acceptable terms, we may not be able to develop or enhance our products, obtain the required regulatory clearances or approvals, achieve long term strategic objectives, take advantage of future opportunities, or respond to competitive pressures or unanticipated customer requirements. Any of these events could adversely affect our ability to achieve our development and commercialization goals, which could have a material and adverse effect on our business, results of operations and financial condition. Further, as a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive.
Our net sales and net loss for the three and six months ended on June 30, 2021 and 2020 are as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
(In thousands) | 2021 |  | 2020 |  | 2021 |  | 2020
Net sales | $ | 17,699 |  |  | $ | 15,287 |  |  | $ | 32,382 |  |  | $ | 29,632 |
Net loss | (5,566) |  |  | (3,711) |  |  | (12,947) |  |  | (9,613) |
Basic and diluted loss per common share | $ | (0.08) |  |  | $ | (0.06) |  |  | $ | (0.20) |  |  | $ | (0.16) |

Net Sales
Net sales consist of gross sales less discounts and returns. The following table sets forth our total net sales by reportable segment:

| Three Months Ended June 30, |  | Six Months Ended June 30,
(In thousands) | 2021 |  | 2020 |  | % Change |  | 2021 |  | 2020 |  | % Change
Net sales: |  |  |  |  |  |  |  |  |  |  |
Consumer Products | $ | 15,396 |  |  | $ | 11,720 |  |  | 31 | % |  | $ | 27,833 |  |  | $ | 22,864 |  |  | 22 | %
Ingredients | 1,504 |  |  | 2,850 |  |  | (47) |  |  | 2,819 |  |  | 5,325 |  |  | (47) |
Analytical reference standards and services | 799 |  |  | 717 |  |  | 11 |  |  | 1,730 |  |  | 1,443 |  |  | 20 |
Total net sales | $ | 17,699 |  |  | $ | 15,287 |  |  | 16 | % |  | $ | 32,382 |  |  | $ | 29,632 |  |  | 9 | %

27

Table of Contents
Total net sales increased by approximately 16% and 9% for the three and six months ended June 30, 2021, compared to the same period in 2020, respectively. Changes in sales for the periods indicated were primarily driven by the following:
•TRU NIAGEN® sales for the consumer products segment continues to increase after the Company's strategic shift towards consumer products in 2017. Our e-commerce sales for TRU NIAGEN® increased approximately $2.5 million, or 31% for the three months ended June 30, 2021 compared to same period in 2020 and $3.9 million, or 24% for the six months ended June 30, 2021 compared to the same period in 2020. Additionally, we began distributing TRU NIAGEN® at Walmart™ stores across the United States beginning in June 2021.
•Our ingredients segment has seen decreased sales in the first half of 2021 compared to the first half of 2020. In 2021, the Company did not ship NIAGEN® to Thorne Research Inc., a former customer who filed a petition on December 1, 2020 for IPR of the ‘086 Patent which ChromaDex Inc. exclusively licenses from Dartmouth College. For more information, see Note 12, Commitments and Contingencies, Legal Proceedings in the Notes to the Consolidated Financial Statements, included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
•The analytical reference standards and services segment experienced increased demand from existing customers in the first half of 2021 driving the increase in sales. Due to the effects of COVID-19, the Company saw lower demand for analytical reference standards during 2020.
Cost of Sales
Cost of sales include raw materials, labor, overhead, and delivery costs. The following table sets forth our total cost of sales by reportable segment:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| Amount |  | % of net sales |  | Amount |  | % of net sales
(In thousands) | 2021 |  | 2020 |  | 2021 |  | 2020 |  | 2021 |  | 2020 |  | 2021 |  | 2020
Cost of sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consumer Products | $ | 5,547 |  |  | $ | 4,339 |  |  | 36 | % |  | 37 | % |  | $ | 9,750 |  |  | $ | 8,641 |  |  | 35 | % |  | 38 | %
Ingredients | 675 |  |  | 1,135 |  |  | 45 |  |  | 40 |  |  | 1,238 |  |  | 2,191 |  |  | 44 |  |  | 41 |
Analytical reference standards and services | 667 |  |  | 725 |  |  | 83 |  |  | 101 |  |  | 1,350 |  |  | 1,401 |  |  | 78 |  |  | 97 |
Total cost of sales | $ | 6,889 |  |  | $ | 6,199 |  |  | 39 | % |  | 41 | % |  | $ | 12,338 |  |  | $ | 12,233 |  |  | 38 | % |  | 41 | %

Cost of sales, as a percentage of net sales, decreased by 2% and 3% for the three and six months ended June 30, 2021, compared to the same period in 2020, respectively. Changes in cost of sales were primarily driven by the following:
•Cost of sales, as a percentage of net sales, for the consumer products segment decreased by 1% and 3% for the three and six months ended June 30, 2021, respectively, compared to the same period in 2020. The decreases were driven by our product mix, cost savings initiatives and overall efficiencies of our supply chain.
•Cost of sales, as a percentage of net sales, for the ingredients segment increased by 5% and 3% for the three and six months ended June 30, 2021, compared to the comparable period in 2020. Costs were lower in the prior year due to a rebate from a supplier for efficiency initiatives, which was recorded in the second quarter of 2020.
•Cost of sales, as a percentage of net sales for the analytical reference standards and services segment, decreased 18% and 19% for the three and six months ended June 30, 2021, compared to the comparable period in 2020. The increase in sales of analytical reference standards led to a higher labor and overhead utilization rate, which resulted in our cost of sales decreasing as a percentage of net sales.
28

Table of Contents
Gross Profit
Gross profit is net sales less the cost of sales and is affected by a number of factors including business and product mix, competitive pricing and costs of products, labor, overhead, services and delivery. The following table sets forth our total gross profit by reportable segment:

| Three Months Ended June 30, |  | Six Months Ended June 30,
(In thousands) | 2021 |  | 2020 |  | % Change |  | 2021 |  | 2020 |  | % Change
Gross profit: |  |  |  |  |  |  |  |  |  |  |
Consumer Products | $ | 9,849 |  |  | $ | 7,381 |  |  | 33 | % |  | $ | 18,083 |  |  | $ | 14,223 |  |  | 27 | %
Ingredients | 829 |  |  | 1,715 |  |  | (52) |  |  | 1,581 |  |  | 3,134 |  |  | (50) |
Analytical reference standards and services | 132 |  |  | (8) |  |  | 1,750 |  |  | 380 |  |  | 42 |  |  | 805 |
Total gross profit | $ | 10,810 |  |  | $ | 9,088 |  |  | 19 | % |  | $ | 20,044 |  |  | $ | 17,399 |  |  | 15 | %

•The consumer products segment posted gross profit of $9.8 million and $18.1 million for the three and six months ended June 30, 2021, an increase of 33% and 27%, respectively, compared to the comparable periods in 2020. The increased gross profit was due to higher sales, product mix, cost savings initiatives and efficiencies within our supply chain operations.
•The ingredients segment posted gross profit of $0.8 million and $1.6 million for the three and six months ended June 30, 2021, a decrease of 52% and 50%, respectively, compared to the comparable period in 2020. The decreased gross profit for the ingredients segment was largely due to lower sales in 2021 compared to 2020, paired with lower expenses in 2020 due to a supplier rebate recorded during the second quarter of 2020.
•The increased gross profit for the analytical reference standards and services segment was primarily driven by increased sales paired with fixed supply chain labor and overhead costs which did not increase in proportion to sales, yielding higher profit margin. These fixed labor and overhead costs make up a substantial portion of the costs of sales.
Operating Expenses-Sales and Marketing
Sales and marketing expenses consist of salaries, advertising, public relations and marketing expenses. Sales and marketing expenses by reportable segment were as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
(In thousands) | 2021 |  | 2020 |  | % Change |  | 2021 |  | 2020 |  | % Change
Sales and marketing expenses: |  |  |  |  |  |  |  |  |  |  |
Consumer Products | $ | 6,190 |  |  | $ | 4,743 |  |  | 31 | % |  | $ | 12,301 |  |  | $ | 9,152 |  |  | 34 | %
Ingredients | 1 |  |  | 76 |  |  | (99) |  |  | 11 |  |  | (8) |  |  | 238 |
Analytical reference standards and services | 41 |  |  | 140 |  |  | (71) |  |  | 178 |  |  | 262 |  |  | (32) |
Total sales and marketing expenses | $ | 6,232 |  |  | $ | 4,959 |  |  | 26 | % |  | $ | 12,490 |  |  | $ | 9,406 |  |  | 33 | %

•For the consumer products segment, the increase during the three and six months ended June 30, 2021 is largely due to direct marketing expenses associated with social media, public relations and other customer awareness and acquisition programs, as well as increased staffing.
•For the ingredients segment, selling and marketing expenses were approximately $1k and $11k during the three and six months ended June 30, 2021. The credit to expense for the six months ended June 30, 2020 relates to a reversal of approximately $114,000 of certain accrued commission expense during the first quarter of 2020, as we were no longer obligated to pay the commission. During the first half of 2021, we continued to decrease our sales and marketing efforts within our ingredients segment to continue our strategic focus on our consumer products segment.
•For the analytical reference standards and services segment, the selling and marketing expenses decreased by 71% and 32% during the three and six months ended June 30, 2021. During the first half of 2021, we continued to decrease our sales and marketing efforts within our analytical reference standards and services segment to continue our strategic focus on our consumer products segment.
29

Table of Contents
Operating Expenses-Research and Development
Research and development expenses consist primarily of clinical trials, regulatory approvals, product development and process development expenses. Research and development expenses by reportable segment were as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
(In thousands) | 2021 |  | 2020 |  | % Change |  | 2021 |  | 2020 |  | % Change
Research and development expenses: |  |  |  |  |  |  |  |  |  |  |
Consumer Products | $ | 926 |  |  | $ | 765 |  |  | 21 | % |  | $ | 1,644 |  |  | $ | 1,453 |  |  | 13 | %
Ingredients | 78 |  |  | 130 |  |  | (40) |  |  | 147 |  |  | 251 |  |  | (41) |
Total research and development expenses | $ | 1,004 |  |  | $ | 895 |  |  | 12 | % |  | $ | 1,791 |  |  | $ | 1,704 |  |  | 5 | %

We allocate the research and development expenses related to our NIAGEN® branded ingredient to the consumer products and ingredients segment, based on revenues recorded. Overall, our research and development expenses remained substantially similar for the three and six months ended June 30, 2021 compared to the comparable periods in 2020.
Operating Expenses-General and Administrative
General and administrative expenses consist of general company administration, legal, royalties, IT, accounting and executive management expenses. General and administrative expenses are not allocated by segment and instead are classified under our Corporate and Other category. General and administrative expenses for the periods indicated were as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
(In thousands) | 2021 |  | 2020 |  | % Change |  | 2021 |  | 2020 |  | % Change
General and administrative | 9,128 |  |  | 6,921 |  |  | 32 | % |  | 18,679 |  |  | 15,866 |  |  | 18 | %

•The increase in general and administrative expenses for the three and six months ended June 30, 2021, compared to the comparable period in 2020 was largely due to an increase in legal expenses. Our legal expenses increased to approximately $4.2 million and $9.2 million in the three and six months ended June 30, 2021, compared to approximately $1.8 million and $4.2 million in the comparable periods in 2020 due to increased activity in our ongoing litigations. For additional details see Note 12, Commitments and Contingencies, Legal Proceedings in the Notes to the Consolidated Financial Statements, included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
•For the three and six months ended June 30, 2021, we did not incur significant severance and restructuring expenses while we incurred approximately $0.3 million and $1.2 million in the comparable periods in 2020. These expenses relate to realignment of the business operations to reduce redundancies and improve efficiencies as we scale the business.
30

Table of Contents
Income Taxes
Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. At June 30, 2021 and June 30, 2020, we maintained a full valuation allowance against the entire deferred income tax balance which resulted in an effective tax rate of approximately 0% for the three and six months ended June 30, 2021, and June 30, 2020, respectively. As defined in ASC 740, Income Taxes, future realization of the tax benefit will depend on the existence of sufficient taxable income, including the expectation of continued future taxable income.
Depreciation and Amortization
Depreciation expense was approximately $0.4 million for both of the six months ended June 30, 2021 and June 30, 2020. We depreciate our assets on a straight-line basis, based on the estimated useful lives of the respective assets.
Amortization expense of intangible assets was approximately $0.1 million for both of the six months ended June 30, 2021 and June 30, 2020. We amortize intangible assets using a straight-line method, generally over 10 years. For licensed patent rights, the useful lives are 10 years or the remaining term of the patents underlying licensing rights, whichever is shorter. The useful lives of subsequent milestone payments that are capitalized are the remaining useful life of the initial licensing payment that was capitalized.
Amortization expense of right of use assets for the six months ended June 30, 2021 was approximately $0.3 million as compared to $0.2 million for the six months ended June 30, 2020.
Liquidity and Capital Resources
From inception through June 30, 2021, we have incurred aggregate losses of approximately $154.8 million. These losses are primarily due to expenses associated with the development and expansion of our operations and investments to protect our intellectual property, including litigation-related expenses. These operations have been financed through capital contributions, the issuance of common stock and warrants through private placements, and the issuance of debt.
Our board of directors periodically reviews our capital requirements in light of our proposed business plan. Our future capital requirements will remain dependent upon a variety of factors, including cash flow from operations, the ability to increase sales, increasing our gross profits from current levels, reducing selling and administrative expenses as a percentage of net sales, continued development of customer relationships, and our ability to market our new products successfully. However, based on our results from operations, we may determine that we need additional financing to implement our business plan. There can be no assurance that any such financing will be available on terms favorable to us or at all. Without adequate financing we may have to delay or terminate product and service expansion and curtail certain selling, general and administrative expenses. Any inability to raise additional financing would have a material adverse effect on us.
Pursuant to the Financing on February 23, 2021, we received proceeds of $24.9 million, net of offering costs. Additionally, in June 2021, under the ATM facility, we received proceeds of $1.9 million, net of offering costs and commissions.
While we anticipate that our current cash, cash equivalents, and available line of credit up to $7.0 million from Western Alliance Bank will be sufficient to meet our projected operating plans for at least the next twelve months, we may seek additional funds, either through additional equity or debt financings or collaborative agreements or from other sources. In June 2020, we filed a $125.0 million registration statement on Form S-3 with the Commission, utilizing a “shelf” registration process. Under this shelf registration process, we may sell securities from time to time, including up to $50.0 million, of which approximately $47.8 million remains available, pursuant to the ATM Facility.
As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive.
31

Table of Contents
Net cash used in operating activities
Net cash used in operating activities for the six months ended June 30, 2021 was approximately $13.3 million as compared to approximately $6.8 million for the six months ended June 30, 2020. Along with the net loss, increases in our trade receivables and inventories and a decrease in our accrued expenses were the largest uses of cash during the six months ended June 30, 2021, partially offset by an increase in accounts payable and noncash share-based compensation expense. Net cash used in operating activities for the six months ended June 30, 2020 largely reflects the net loss, a decrease in allowance for doubtful trade receivables and an increase in inventories, partially offset by a decrease in trade receivables, increase in accrued expenses and noncash share-based compensation expense.
We expect our operating cash flows to fluctuate significantly in future periods as a result of fluctuations in our operating results, shipment timetables, trade receivable collections, inventory management, and the timing of our payments, among other factors.
Net cash used in investing activities
Net cash used in investing activities was approximately $0.3 million for the six months ended June 30, 2021, compared to approximately $0.1 million for the six months ended June 30, 2020. Net cash used in investing activities for the six months ended June 30, 2021 and 2020 mainly consisted of purchases of leasehold improvements and equipment.
Net cash provided by financing activities
Net cash provided by financing activities was approximately $35.7 million for the six months ended June 30, 2021, compared to approximately $7.0 million for the six months ended June 30, 2020. Net cash provided by financing activities for the six months ended June 30, 2021 primarily consisted of proceeds from the issuance of common stock pursuant to the Financing, ATM Facility transaction and the exercise of stock options. Net cash provided by financing activities for the six months ended June 30, 2020 consisted of proceeds from the issuance of common stock and the exercise of stock options.
Contractual Obligations and Commitments
During the six months ended June 30, 2021, there were no material changes outside of the ordinary course of business in the specified contractual obligations disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as contained in our Annual Report, other than as disclosed in “Item 1 Financial Statements” of this Quarterly Report on Form 10-Q.
Off-Balance Sheet Arrangements
During the six months ended June 30, 2021, we had no material off-balance sheet arrangements.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
32

Table of Contents
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the supervision of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
During 2020, we identified a material weakness in our internal control over financial reporting. The material weakness resulted from a deficiency in our disclosure controls and procedures which could have resulted in the Company not disclosing a material potential loss requiring a qualitative disclosure and recording a liability in the consolidated financial statements under ASC 450 - Contingencies. Specifically, the Company failed to disclose in its Quarterly Report on Form 10-Q for the period ended September 30, 2020 that the Company received a letter in September 2020 from a customer requesting a full refund of approximately $1.6 million of NIAGEN® it purchased, alleging breaches of the supply agreement between the parties, and failed to record a liability in its financial statements for such quarter.
The Company is still in the process of analyzing and addressing the material weakness. The material weakness will not be considered remediated until the applicable remedial control operates for a sufficient period of time and management has concluded, through testing, that this control is operating effectively. We expect that the remediation of this material weakness will be completed prior to the end of year 2021. As such, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2021, our disclosure controls and procedures were not effective as a result of the material weakness in our internal control over financial reporting discussed above.
Our Chief Executive Officer and Chief Financial Officer believe that, notwithstanding the material weakness discussed above, the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented.
Changes in Internal Control over Financial Reporting
An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any change in our internal control over financial reporting (as defined in Rule 13a−15(f) promulgated under the Exchange Act) that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Other than addressing the material weakness as discussed above, there were no changes in internal control over financial reporting that occurred during the Company’s second fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting
33

Table of Contents
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
For a description of our legal proceedings, see Note 12, Commitments and Contingencies, Legal Proceedings in the Notes to the Consolidated Financial Statements, included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Item 1A. RISK FACTORS
Investing in our common stock involves a high degree of risk. Current investors and potential investors should consider carefully the risks and uncertainties described below and in our Annual Report, together with all other information contained in this Quarterly Report on Form 10-Q and our Annual Report, including our financial statements, the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before making investment decisions with respect to our common stock. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. Under these circumstances, the trading price and value of our common stock could decline, and you may lose all or part of your investment. The risks and uncertainties described in this Quarterly Report on Form 10-Q and in our Annual Report are not the only ones facing our Company. Additional risks and uncertainties of which we are not presently aware, or that we currently consider immaterial, may also impair our business operations. The risk factors set forth below that are marked with an asterisk (*) contain changes to the similarly titled risk factors included in Part I, Item 1A of our Annual Report.
Risks Related to our Company and our Business
*The COVID-19 pandemic has adversely affected, and is expected to continue to pose risks to, our business, results of operations, financial condition and cash flows, and other epidemics or outbreaks of infectious diseases may have a similar impact.
As previously disclosed, we face risks related to the ongoing COVID-19 pandemic. COVID-19 has spread across the globe since 2020 and is impacting economic activity worldwide. COVID-19 has caused disruption and volatility in the global capital markets, and has caused an economic slowdown. The COVID-19 pandemic and its associated economic uncertainty may negatively impact our sales volumes in 2021. In response to COVID-19, national and local governments around the world have instituted certain measures, including travel bans, prohibitions on group events and gatherings, shutdowns of certain businesses, curfews, shelter-in-place orders and recommendations to practice social distancing. The duration of these measures is unknown, may be extended and additional measures may be imposed.
Among the potential effects of COVID-19 include, but are not limited to, the following:
•Reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, and reduced business and consumer spending, which may adversely affect our results of operations by reducing our sales, margins and/or net income as a result of a slowdown in customer orders.
•Reduced demand for our products due to store closures and reduced operating hours of our customers.
•Disruptions in supply chain, leading to inadequate levels of inventory that may lower our sales.
For example, our retail business, including sales to A.S. Watson group and other partners in international markets, has been impacted by the effects of COVID-19, due to store closures and reduced operating hours.
To the extent the COVID-19 pandemic adversely affects our business, results of operations, financial condition and cash flows, it may also heighten many of the other risks described in this section. The ultimate impact of COVID-19 on our business, results of operations, financial condition and cash flows is dependent on future developments, including the duration of the pandemic and the related length of its impact on the global economy, which are uncertain and cannot be predicted at this time.
34

Table of Contents
*We have a history of operating losses, may need additional financing to meet our future long-term capital requirements and may be unable to raise sufficient capital on favorable terms or at all.
We have recorded a net loss of approximately $12.9 million for the six months ended June 30, 2021 and we have a history of losses and may continue to incur operating and net losses for the foreseeable future. We incurred net losses of approximately $19.9 million and $32.1 million for the years ended December 31, 2020 and December 31, 2019, respectively. As of June 30, 2021, our accumulated deficit was approximately $154.8 million. We have not achieved profitability on an annual basis. We may not be able to reach a level of revenue to continue to achieve and sustain profitability. If our revenues grow slower than anticipated, or if operating expenses exceed expectations, then we may not be able to achieve and sustain profitability in the near future or at all, which may depress our stock price.
As of June 30, 2021, our cash and cash equivalents totaled approximately $38.8 million. While we anticipate that our current cash, cash equivalents, cash to be generated from operations and available line of credit up to $7 million from Western Alliance Bank will be sufficient to meet our projected operating plans through at least the next twelve months, we may require additional funds, either through additional equity or debt financings, including pursuant to the At Market Issuance Sales Agreement, dated as of June 12, 2020, with B. Riley FBR, Inc. and Raymond James & Associates, Inc. (the “ATM Facility”), or collaborative agreements or from other sources. We have no commitments to obtain such additional financing, and we may not be able to obtain any such additional financing on terms favorable to us, or at all. Further, as a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive. If adequate financing is not available, the Company will further delay, postpone or terminate product and service expansion and curtail certain selling, general and administrative operations. The inability to raise additional financing may have a material adverse effect on the future performance of the Company.
Our capital requirements will depend on many factors.
Our capital requirements will depend on many factors, including:
•the revenues generated by sales of our products;
•the costs associated with expanding our sales and marketing efforts, including efforts to hire independent agents and sales representatives and obtain required regulatory approvals and clearances;
•the expenses we incur in developing and commercializing our products, including the cost of obtaining and maintaining regulatory approvals; and
•unanticipated general and administrative expenses, including expenses involved with our ongoing litigation with Elysium.
Because of these factors, we may seek to raise additional capital within the next twelve months both to meet our projected operating plans after the next twelve months and to fund our longer term strategic objectives. Additional capital may come from public and private equity or debt offerings, borrowings under lines of credit or other sources. These additional funds may not be available on favorable terms, or at all. There can be no assurance we will be successful in raising these additional funds. Furthermore, if we issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution and the new equity or debt securities we issue may have rights, preferences and privileges senior to those of our existing stockholders. In addition, if we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to our products or proprietary technologies, or grant licenses on terms that are not favorable to us. If we cannot raise funds on acceptable terms, we may not be able to develop or enhance our products, obtain the required regulatory clearances or approvals, execute our business plan, take advantage of future opportunities, or respond to competitive pressures or unanticipated customer requirements. Any of these events could adversely affect our ability to achieve our development and commercialization goals, which could have a material and adverse effect on our business, results of operations and financial condition.
35

Table of Contents
Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain and may be inadequate, which would have a material and adverse effect on us.
Our success depends significantly on our ability to protect our proprietary rights to the technologies used in our products. We rely on patent protection, as well as a combination of copyright, trade secret and trademark laws and nondisclosure, confidentiality and other contractual restrictions to protect our proprietary technology, including our licensed technology. However, these legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. For example, our pending United States and foreign patent applications may not issue as patents in a form that will be advantageous to us or may issue and be subsequently successfully challenged by others and invalidated. In addition, our pending patent applications include claims to material aspects of our products and procedures that are not currently protected by issued patents. Both the patent application process and the process of managing patent disputes can be time consuming and expensive. Competitors may be able to design around our patents or develop products which provide outcomes which are comparable or even superior to ours. Steps that we have taken to protect our intellectual property and proprietary technology, including entering into confidentiality agreements and intellectual property assignment agreements with some of our officers, employees, consultants and advisors, may not provide us with meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements. Furthermore, the laws of foreign countries may not protect our intellectual property rights to the same extent as do the laws of the United States.
In the event a competitor infringes our licensed or pending patent or other intellectual property rights, enforcing those rights may be costly, uncertain, difficult and time consuming. Even if successful, litigation to enforce our intellectual property rights or to defend our patents against challenge could be expensive and time consuming and could divert our management’s attention. We may not have sufficient resources to enforce our intellectual property rights or to defend our patents rights against a challenge. The failure to obtain patents and/or protect our intellectual property rights could have a material and adverse effect on our business, results of operations and financial condition.
Our patents and licenses may be subject to challenge on validity grounds, and our patent applications may be rejected.
We rely on our patents, patent applications, licenses and other intellectual property rights to give us a competitive advantage. Whether a patent is valid, or whether a patent application should be granted, is a complex matter of science and law, and therefore we cannot be certain that, if challenged, our patents, patent applications and/or other intellectual property rights would be upheld. If one or more of those patents, patent applications, licenses and other intellectual property rights are invalidated, rejected or found unenforceable, that could reduce or eliminate any competitive advantage we might otherwise have had.
We may become subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from developing our products, require us to obtain licenses from third parties or to develop non-infringing alternatives and subject us to substantial monetary damages.
Third parties could, in the future, assert infringement or misappropriation claims against us with respect to products we develop. Whether a product infringes a patent or misappropriates other intellectual property involves complex legal and factual issues, the determination of which is often uncertain. Therefore, we cannot be certain that we have not infringed the intellectual property rights of others. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for use related to the use or manufacture of our products, and our potential competitors may assert that some aspect of our product infringes their patents. Because patent applications may take years to issue, there also may be applications now pending of which we are unaware that may later result in issued patents upon which our products could infringe. There also may be existing patents or pending patent applications of which we are unaware upon which our products may inadvertently infringe.
Any infringement or misappropriation claim could cause us to incur significant costs, place significant strain on our financial resources, divert management’s attention from our business and harm our reputation. If the relevant patents in such claim were upheld as valid and enforceable and we were found to infringe them, we could be prohibited from manufacturing or selling any product that is found to infringe unless we could obtain licenses to use the technology covered by the patent or are able to design around the patent. We may be unable to obtain such a license on terms acceptable to us, if at all, and we may not be able to redesign our products to avoid infringement, which could materially impact our revenue. A court could also order us to pay compensatory damages for such infringement, plus prejudgment interest and could, in addition, treble the compensatory damages and award attorney fees. These damages could be substantial and could harm our reputation, business, financial condition and operating results. A court also could enter orders that temporarily, preliminarily or permanently enjoin us and our customers from making, using, or selling products, and could enter an order mandating that we undertake certain remedial activities. Depending on the nature of the relief ordered by the court, we could become liable for additional damages to third parties.
36

Table of Contents
The prosecution and enforcement of patents licensed to us by third parties are not within our control. Without these technologies, our products may not be successful and our business would be harmed if the patents were infringed on or misappropriated without action by such third parties.
We have obtained licenses from third parties for patents and patent application rights related to the products we are developing, allowing us to use intellectual property rights owned by or licensed to these third parties. We do not control the maintenance, prosecution, enforcement or strategy for many of these patents or patent application rights and as such are dependent in part on the owners of the intellectual property rights to maintain their viability. If any third-party licensor is unable to successfully maintain, prosecute or enforce the licensed patents and/or patent application rights related to our products, we may become subject to infringement or misappropriate claims or lose our competitive advantage. Without access to these technologies or suitable design-around or alternative technology options, our ability to conduct our business could be impaired significantly.
*We are currently engaged in substantial and complex litigation with Elysium Health, Inc. and Elysium Health LLC (collectively, "Elysium"), the outcome of which could materially harm our business and financial results.
The litigation includes multiple complaints and counterclaims by us and Elysium in venues in California and New York, as well as a patent infringement complaint filed by the Company and Trustees of Dartmouth College. For further details on this litigation, please refer to Note 12, Commitments and Contingencies, Legal Proceedings in the Notes to the Consolidated Financial Statements, included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
The litigation is substantial and complex, and it has caused and could continue to cause us to incur significant costs, as well as distract our management over an extended period. The litigation may substantially disrupt our business and we cannot assure you that we will be able to resolve the litigation on terms favorable to us. If we are unsuccessful in resolving the litigation on favorable terms to us, we may be forced to pay compensatory and punitive damages and restitution for any royalty payments that we received from Elysium, which payments could materially harm our business, or be subject to other remedies, including injunctive relief. We cannot predict the outcome of our litigation with Elysium, which could have any of the results described above or other results that could materially adversely affect our business.
*Interruptions in our relationships or declines in our business with major customers could materially harm our business and financial results.
A.S. Watson Group accounted for approximately 14% of our sales during the six months ended June 30, 2021. Any interruption in our relationship or decline in our business with this customer or other customers upon whom we become highly dependent could cause harm to our business. Factors that could influence our relationship with our customers upon whom we may become highly dependent include:
•our ability to maintain our products at prices that are competitive with those of our competitors;
•our ability to maintain quality levels for our products sufficient to meet the expectations of our customers;
•our ability to produce, ship and deliver a sufficient quantity of our products in a timely manner to meet the needs of our customers;
•our ability to continue to develop and launch new products that our customers feel meet their needs and requirements, with respect to cost, timeliness, features, performance and other factors;
•our ability to provide timely, responsive and accurate customer support to our customers; and
•the ability of our customers to effectively deliver, market and increase sales of their own products based on ours.
Our future success largely depends on sales of our TRU NIAGEN® product.
In connection with our strategic shift from an ingredient and testing company to a consumer-focused company, we expect to generate a significant percentage of our future revenue from sales of our TRU NIAGEN® product. As a result, the market acceptance of TRU NIAGEN® is critical to our continued success, and if we are unable to expand market acceptance of TRU NIAGEN®, our business, results of operations, financial condition, liquidity and growth prospects would be materially adversely affected.
37

Table of Contents
Our TRU NIAGEN® products are not approved by the United States Food and Drug Administration or any foreign regulatory authority to mitigate, prevent, treat, diagnose or cure COVID-19 or any other disease or condition.
In November 2020, we received a warning letter (the “Letter”) from the FDA and Federal Trade Commission (“FTC”) and in April 2021 we received an additional warning letter from only the FTC. For more information, see Note 12, Commitments and Contingencies, Contingencies in the Notes to the Consolidated Financial Statements, included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Our TRU NIAGEN® products are not approved by the FDA or any foreign regulatory authority to mitigate, prevent, treat, diagnose or cure COVID-19 or any other disease or condition, and are not intended for such use, and may never be approved for such use by the FDA or any foreign regulatory authority.
Decline in the state of the global economy and financial market conditions could adversely affect our ability to conduct business and our results of operations.
Global economic and financial market conditions, including disruptions in the credit markets and the impact of the global economic deterioration may materially impact our customers and other parties with whom we do business. For example, the COVID-19 pandemic and actions taken to slow its spread, have caused the global credit and financial markets to experience extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. These conditions could negatively affect our future sales of our ingredient lines as many consumers consider the purchase of nutritional products discretionary. Decline in general economic and financial market conditions could materially adversely affect our financial condition and results of operations. Specifically, the impact of these volatile and negative conditions may include decreased demand for our products and services, a decrease in our ability to accurately forecast future product trends and demand, and a negative impact on our ability to timely collect receivables from our customers. The foregoing economic conditions may lead to increased levels of bankruptcies, restructurings and liquidations for our customers, scaling back of research and development expenditures, delays in planned projects and shifts in business strategies for many of our customers. Such events could, in turn, adversely affect our business through loss of sales.
We may need to increase the size of our organization, and we can provide no assurance that we will successfully expand operations or manage growth effectively.
Our significant increase in the scope and the scale of our product launches, including the hiring of additional personnel, has resulted in significantly higher operating expenses. As a result, we anticipate that our operating expenses will continue to increase. Expansion of our operations may also cause a significant demand on our management, finances and other resources. Our ability to manage the anticipated future growth, should it occur, will depend upon a significant expansion of our accounting and other internal management systems and the implementation and subsequent improvement of a variety of systems, procedures and controls. There can be no assurance that significant problems in these areas will not occur. Any failure to expand these areas and implement and improve such systems, procedures and controls in an efficient manner at a pace consistent with our business could have a material adverse effect on our business, financial condition and results of operations. There can be no assurance that our attempts to expand our marketing, sales, manufacturing and customer support efforts will be successful or will result in additional sales or profitability in any future period. As a result of the expansion of our operations and the anticipated increase in our operating expenses, as well as the difficulty in forecasting revenue levels, we expect to continue to experience significant fluctuations in our results of operations.
Changes in our business strategy, including entering the consumer product market, or restructuring of our businesses may increase our costs or otherwise affect the profitability of our businesses.
As changes in our business environment occur we may adjust our business strategies to meet these changes or we may otherwise decide to restructure our operations or businesses or assets. In addition, external events including changing technology, changing consumer patterns and changes in macroeconomic conditions may impair the value of our assets. When these changes or events occur, we may incur costs to change our business strategy and may need to write down the value of assets. In any of these events, our costs may increase, we may have significant charges associated with the write-down of assets or returns on new investments may be lower than prior to the change in strategy or restructuring. For example, if we are not successful in developing our consumer product business, our sales may decrease and our costs may increase
38

Table of Contents
The success of our consumer product and ingredient business is linked to the size and growth rate of the vitamin, mineral and dietary supplement market and an adverse change in the size or growth rate of that market could have a material adverse effect on us.
An adverse change in the size or growth rate of the vitamin, mineral and dietary supplement market could have a material adverse effect on our business. Underlying market conditions are subject to change based on economic conditions, consumer preferences and other factors that are beyond our control, including media attention and scientific research, which may be positive or negative.
The future growth and profitability of our consumer product business will depend in large part upon the effectiveness and efficiency of our marketing efforts and our ability to select effective markets and media in which to market and advertise.
Our consumer products business success depends on our ability to attract and retain customers, which significantly depends on our marketing practices. Our future growth and profitability will depend in large part upon the effectiveness and efficiency of our marketing efforts, including our ability to:
•create greater awareness of our brand;
•identify the most effective and efficient levels of spending in each market, media and specific media vehicle;
•determine the appropriate creative messages and media mix for advertising, marketing and promotional expenditures;
•effectively manage marketing costs (including creative and media) to maintain acceptable customer acquisition costs;
•acquire cost-effective television advertising;
•select the most effective markets, media and specific media vehicles in which to market and advertise; and
•convert consumer inquiries into actual orders.
Unfavorable publicity or consumer perception of our products and any similar products distributed by other companies could have a material adverse effect on our business.
We believe the nutritional supplement market is highly dependent upon consumer perception regarding the safety, efficacy and quality of nutritional supplements generally, as well as of products distributed specifically by us. Consumer perception of our products can be significantly influenced by scientific research or findings, regulatory investigations, litigation, national media attention and other publicity regarding the consumption of nutritional supplements. We cannot assure you that future scientific research, findings, regulatory proceedings, litigation, media attention or other favorable research findings or publicity will be favorable to the nutritional supplement market or any product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, such earlier research reports, findings or publicity could have a material adverse effect on the demand for our products and consequently on our business, results of operations, financial condition and cash flows.
Our dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, if accurate or with merit, could have a material adverse effect on the demand for our products, the availability and pricing of our ingredients, and our business, results of operations, financial condition and cash flows. Further, adverse public reports or other media attention regarding the safety, efficacy and quality of nutritional supplements in general, or our products specifically, or associating the consumption of nutritional supplements with illness, could have such a material adverse effect. Any such adverse public reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers’ failure to consume such products appropriately or as directed and the content of such public reports and other media attention may be beyond our control.
39

Table of Contents
We may incur material product liability claims, which could increase our costs and adversely affect our reputation, revenues and operating income.
As a consumer product and ingredient supplier we market and manufacture products designed for human and animal consumption, we are subject to product liability claims if the use of our products is alleged to have resulted in injury. Our products consist of vitamins, minerals, herbs and other ingredients that are classified as food ingredients, dietary supplements, or natural health products, and, in most cases, are not necessarily subject to pre-market regulatory approval in the United States. Some of our products contain innovative ingredients that do not have long histories of human consumption. Previously unknown adverse reactions resulting from human consumption of these ingredients could occur. In addition, the products we sell are produced by third-party manufacturers. As a marketer of products manufactured by third parties, we also may be liable for various product liability claims for products we do not manufacture. We may, in the future, be subject to various product liability claims, including, among others, that our products include inadequate instructions for use or inadequate warnings concerning possible side effects and interactions with other substances. A product liability claim against us could result in increased costs and could adversely affect our reputation with our customers, which, in turn, could have a materially adverse effect on our business, results of operations, financial condition and cash flows.
We acquire ingredients for our products from foreign suppliers, and may be negatively affected by the risks associated with international trade and importation issues.
We acquire ingredients for a number of our products from suppliers outside of the United States. Accordingly, the acquisition of these ingredients is subject to the risks generally associated with importing raw materials, including, among other factors, delays in shipments, changes in economic and political conditions, quality assurance, health epidemics affecting the region of such suppliers, including COVID-19, nonconformity to specifications or laws and regulations, tariffs, trade disputes and foreign currency fluctuations. While we have a supplier certification program and audit and inspect our suppliers’ facilities as necessary both in the United States and internationally, we cannot assure you that raw materials received from suppliers outside of the United States will conform to all specifications, laws and regulations. There have in the past been quality and safety issues in our industry with certain items imported from overseas. We may incur additional expenses and experience shipment delays due to preventative measures adopted by the U.S. governments, our suppliers and our company.
The insurance industry has become more selective in offering some types of coverage and we may not be able to obtain insurance coverage in the future.
The insurance industry has become more selective in offering some types of insurance, such as product liability, product recall, property and directors’ and officers’ liability insurance. Our current insurance program is consistent with both our past level of coverage and our risk management policies. However, we cannot assure you that we will be able to obtain comparable insurance coverage on favorable terms, or at all, in the future. Certain of our customers as well as prospective customers require that we maintain minimum levels of coverage for our products. Lack of coverage or coverage below these minimum required levels could cause these customers to materially change business terms or to cease doing business with us entirely.
If we experience product recalls, we may incur significant and unexpected costs, and our business reputation could be adversely affected.
We may be exposed to product recalls and adverse public relations if our products are alleged to be mislabeled or to cause injury or illness, or if we are alleged to have violated governmental regulations. A product recall could result in substantial and unexpected expenditures, which would reduce operating profit and cash flow. In addition, a product recall may require significant management attention. Product recalls may hurt the value of our brands and lead to decreased demand for our products. Product recalls also may lead to increased scrutiny by federal, state or international regulatory agencies of our operations and increased litigation and could have a material adverse effect on our business, results of operations, financial condition and cash flows.
40

Table of Contents
*We depend on key personnel, the loss of any of which could negatively affect our business.
We depend greatly on the collective services of Frank L. Jaksch Jr., Robert N. Fried, Kevin M. Farr and Fadi Karam, who are our Executive Chairman of the Board, Chief Executive Officer, Chief Financial Officer and Chief Marketing Officer, respectively. We also depend greatly on other key employees, including key scientific and marketing personnel. In general, only highly qualified and trained scientists have the necessary skills to develop our products and provide our services. Only marketing personnel with specific experience and knowledge in health care are able to effectively market our products. In addition, some of our manufacturing, quality control, safety and compliance, information technology, sales and e-commerce related positions are highly technical as well. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout the industries in which we compete. Our success will depend, in part, upon our ability to attract and retain additional skilled personnel, which will require substantial additional funds. There can be no assurance that we will be able to find and attract additional qualified employees or retain any such personnel. Our inability to hire qualified personnel, the loss of services of our key personnel, or the loss of services of executive officers or key employees that may be hired in the future may have a material and adverse effect on our business.
Our operating results may fluctuate significantly as a result of a variety of factors, many of which are outside of our control.
We are subject to the following factors, among others, that may negatively affect our operating results:
•the announcement or introduction of new products by our competitors;
•our ability to upgrade and develop our systems and infrastructure to accommodate growth;
•the decision by significant customers to reduce purchases;
•disputes and litigation with competitors;
•our ability to attract and retain key personnel in a timely and cost-effective manner;
•technical difficulties;
•the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure;
•regulation by federal, state or local governments; and
•general economic conditions as well as economic conditions specific to the healthcare industry.
For example, our operating results may be harmed by the effect of the COVID-19 pandemic on global economic conditions. As a result of our limited operating history and the nature of the markets in which we compete, it is extremely difficult for us to make accurate forecasts. We have based our current and future expense levels largely on our investment plans and estimates of future events although certain of our expense levels are, to a large extent, fixed. Assuming our products reach the market, we may be unable to adjust spending in a timely manner to compensate for any unexpected revenue shortfall. Accordingly, any significant shortfall in revenues relative to our planned expenditures would have an immediate adverse effect on our business, results of operations and financial condition. Further, as a strategic response to changes in the competitive environment, we may from time to time make certain pricing, service or marketing decisions that could have a material and adverse effect on our business, results of operations and financial condition. Due to the foregoing factors, our revenues and operating results are and will remain difficult to forecast.
We face significant competition, including changes in pricing.
The markets for our products and services are both competitive and price sensitive. Many of our competitors have significant financial, operations, sales and marketing resources and experience in research and development. Competitors could develop new technologies that compete with our products and services or even render our products obsolete. If a competitor develops superior technology or cost-effective alternatives to our products and services, our business could be seriously harmed.
The markets for some of our products are also subject to specific competitive risks because these markets are highly price competitive. Our competitors have competed in the past by lowering prices on certain products. If they do so again, we may be forced to respond by lowering our prices. This would reduce sales revenues and increase losses. Failure to anticipate and respond to price competition may also impact sales and aggravate losses.
We believe that customers in our markets display a significant amount of loyalty to their supplier of a particular product. To the extent we are not the first to develop, offer and/or supply new products, customers may buy from our competitors or make materials themselves, causing our competitive position to suffer.
41

Table of Contents
Many of our competitors are larger and have greater financial and other resources than we do.
Our products compete and will compete with other similar products produced by our competitors. These competitive products could be marketed by well-established, successful companies that possess greater financial, marketing, distributional, personnel and other resources than we possess. Using these resources, these companies can implement extensive advertising and promotional campaigns, both generally and in response to specific marketing efforts by competitors, and enter into new markets more rapidly to introduce new products. In certain instances, competitors with greater financial resources also may be able to enter a market in direct competition with us, offering attractive marketing tools to encourage the sale of products that compete with our products or present cost features that consumers may find attractive.
We may never develop any additional products to commercialize.
We have invested a substantial amount of our time and resources in developing various new products. Commercialization of these products will require additional development, clinical evaluation, regulatory approval, significant marketing efforts and substantial additional investment before they can provide us with any revenue. Despite our efforts, these products may not become commercially successful products for a number of reasons, including but not limited to:
•we may not be able to obtain regulatory approvals for our products, or the approved indication may be narrower than we seek;
•our products may not prove to be safe and effective in clinical trials;
•we may experience delays in our development program;
•any products that are approved may not be accepted in the marketplace;
•we may not have adequate financial or other resources to complete the development or to commence the commercialization of our products or will not have adequate financial or other resources to achieve significant commercialization of our products;
•we may not be able to manufacture any of our products in commercial quantities or at an acceptable cost;
•rapid technological change may make our products obsolete;
•we may be unable to effectively protect our intellectual property rights or we may become subject to claims that our activities have infringed the intellectual property rights of others; and
•we may be unable to obtain or defend patent rights for our products.
In addition, we may never achieve technical feasibility under the supply agreement with Nestec Ltd., and therefore our sales and profit expectations resulting from this agreement may be reduced.
We may not be able to partner with others for technological capabilities and new products and services.
Our ability to remain competitive may depend, in part, on our ability to continue to seek partners that can offer technological improvements and improve existing products and services that are offered to our customers. We are committed to attempting to keep pace with technological change, to stay abreast of technology changes and to look for partners that will develop new products and services for our customer base. We cannot assure prospective investors that we will be successful in finding partners or be able to continue to incorporate new developments in technology, to improve existing products and services, or to develop successful new products and services, nor can we be certain that newly developed products and services will perform satisfactorily or be widely accepted in the marketplace or that the costs involved in these efforts will not be substantial.
If we fail to maintain adequate quality standards for our products and services, our business may be adversely affected and our reputation harmed.
Dietary supplement, nutraceutical, food and beverage, functional food, analytical laboratories, pharmaceutical and cosmetic customers are often subject to rigorous quality standards to obtain and maintain regulatory approval of their products and the manufacturing processes that generate them. A failure to maintain, or, in some instances, upgrade our quality standards to meet our customers’ needs, could cause damage to our reputation and potentially substantial sales losses.
42

Table of Contents
We may be subject to damages resulting from claims that we, our employees, or our independent contractors have wrongfully used or disclosed alleged trade secrets of others.
Some of our employees were previously employed at other dietary supplement, nutraceutical, food and beverage, functional food, analytical laboratories, pharmaceutical and cosmetic companies. We may also hire additional employees who are currently employed at other such companies, including our competitors. Additionally, consultants or other independent agents with which we may contract may be or have been in a contractual arrangement with one or more of our competitors. We may be subject to claims that these employees or independent contractors have used or disclosed such other party’s trade secrets or other proprietary information. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management. If we fail to defend such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to market existing or new products, which could severely harm our business.
*Litigation may harm our business.
Substantial, complex or extended litigation could cause us to incur significant costs and distract our management. For example, lawsuits by employees, stockholders, collaborators, distributors, customers, competitors or others could be very costly and substantially disrupt our business. Disputes from time to time with such companies, organizations or individuals are not uncommon, and we cannot assure you that we will always be able to resolve such disputes or on terms favorable to us. As further described in Part II, Item 1 of this Quarterly Report on Form 10-Q, we are currently involved in substantial and complex litigation. Unexpected results could cause us to have financial exposure in these matters in excess of recorded reserves and insurance coverage, requiring us to provide additional reserves to address these liabilities, therefore impacting profits.
Our sales and results of operations for our analytical reference standards and services segment depend on our customers’ research and development efforts and their ability to obtain funding for these efforts.
Our analytical reference standards and services segment customers include researchers at pharmaceutical and biotechnology companies, chemical and related companies, academic institutions, government laboratories and private foundations. Fluctuations in the research and development budgets of these researchers and their organizations could have a significant effect on the demand for our products. Our customers determine their research and development budgets based on several factors, including the need to develop new products, the availability of governmental and other funding, competition and the general availability of resources. As we continue to expand our international operations, we expect research and development spending levels in markets outside of the United States will become increasingly important to us.
Research and development budgets fluctuate due to changes in available resources, spending priorities, general economic conditions, institutional and governmental budgetary limitations and mergers of pharmaceutical and biotechnology companies. Our business could be harmed by any significant decrease in life science and high technology research and development expenditures by our customers. In particular, a small portion of our sales has been to researchers whose funding is dependent on grants from government agencies such as the United States National Institute of Health, the National Science Foundation, the National Cancer Institute and similar agencies or organizations. Government funding of research and development is subject to the political process, which is often unpredictable. Other departments, such as Homeland Security or Defense, or general efforts to reduce the United States federal budget deficit could be viewed by the government as a higher priority. Any shift away from funding of life science and high technology research and development or delays surrounding the approval of governmental budget proposals may cause our customers to delay or forego purchases of our products and services, which could seriously damage our business.
Some of our customers receive funds from approved grants at a particular time of year, many times set by government budget cycles. In the past, such grants have been frozen for extended periods or have otherwise become unavailable to various institutions without notice. The timing of the receipt of grant funds may affect the timing of purchase decisions by our customers and, as a result, cause fluctuations in our sales and operating results.
Demand for our products and services are subject to the commercial success of our customers’ products, which may vary for reasons outside our control.
Even if we are successful in securing utilization of our products in a customer’s manufacturing process, sales of many of our products and services remain dependent on the timing and volume of the customer’s production, over which we have no control. The demand for our products depends on regulatory approvals and frequently depends on the commercial success of the customer’s supported product. Regulatory processes are complex, lengthy, expensive, and can often take years to complete.
43

Table of Contents
We may bear financial risk if we underprice our contracts or overrun cost estimates.
In cases where our contracts are structured as fixed price or fee-for-service with a cap, we bear the financial risk if we initially underprice our contracts or otherwise overrun our cost estimates. Such underpricing or significant cost overruns could have a material adverse effect on our business, results of operations, financial condition and cash flows.
We rely on single or a limited number of third-party suppliers for the raw materials required to produce our products.
Our dependence on a limited number of third-party suppliers or on a single supplier, and the challenges we may face in obtaining adequate supplies of raw materials, involve several risks, including limited control over pricing, availability, health epidemics affecting the region of such suppliers (including the coronavirus), quality and delivery schedules. We cannot be certain that our current suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Due to COVID-19, there may be delays in shipments from our suppliers. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our products until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and commercialization of our products, or interrupt production of then existing products that are already marketed, which would have a material adverse effect on our business. For example, W.R. Grace & Co.-Conn. (“Grace”) is the exclusive manufacturer to us for the supply of NR. There is no guarantee that we will be able to continue to contract with Grace for the supply of NR, or that such terms will be favorable to us.
We may not be successful in acquiring complementary businesses or products on favorable terms.
As part of our business strategy, we intend to consider acquisitions of similar or complementary businesses or products. No assurance can be given that we will be successful in identifying attractive acquisition candidates or completing acquisitions on favorable terms. In addition, any future acquisitions will be accompanied by the risks commonly associated with acquisitions. These risks include potential exposure to unknown liabilities of acquired companies or to acquisition costs and expenses, the difficulty and expense of integrating the operations and personnel of the acquired companies, the potential disruption to the business of the combined company and potential diversion of our management's time and attention, the impairment of relationships with and the possible loss of key employees and clients as a result of the changes in management, the incurrence of amortization expenses and write-downs and dilution to the shareholders of the combined company if the acquisition is made for stock of the combined company. In addition, successful completion of an acquisition may depend on consents from third parties, including regulatory authorities and private parties, which consents are beyond our control. There can be no assurance that products, technologies or businesses of acquired companies will be effectively assimilated into the business or product offerings of the combined company or will have a positive effect on the combined company's revenues or earnings. Further, the combined company may incur significant expense to complete acquisitions and to support the acquired products and businesses. Any such acquisitions may be funded with cash, debt or equity, which could have the effect of diluting or otherwise adversely affecting the holdings or the rights of our existing stockholders.
If we experience a significant disruption in our information technology systems or if we fail to implement new systems and software successfully, our business could be adversely affected.
We depend on information systems throughout our company to control our manufacturing processes, process orders, manage inventory, process and bill shipments and collect cash from our customers, respond to customer inquiries, contribute to our overall internal control processes, maintain records of our property, plant and equipment, and record and pay amounts due vendors and other creditors. Due to COVID-19, most of our employees have been working remotely from home and we have depended on communication tools and remote connections to our information technology systems to conduct business virtually. If we were to experience a prolonged disruption in our information systems that involve interactions amongst employees as well as with customers and suppliers, it could result in the loss of sales and customers and/or increased costs, which could adversely affect our overall business operation.
44

Table of Contents
If we are unable to maintain sales, marketing and distribution capabilities or maintain arrangements with third parties to sell, market and distribute our products, our business may be harmed.
To achieve commercial success for our products, we must sell our product lines and/or technologies at favorable prices. In addition to being expensive, maintaining such a sales force is time-consuming. Qualified direct sales personnel with experience in the natural products industry are in high demand, and there can be no assurance that we will be able to hire or retain an effective direct sales team. Similarly, qualified independent sales representatives both within and outside the United States are in high demand, and we may not be able to build an effective network for the distribution of our product through such representatives. There can be no assurance that we will be able to enter into contracts with representatives on terms acceptable to us. Furthermore, there can be no assurance that we will be able to build an alternate distribution framework should we attempt to do so.
We may also need to contract with third parties in order to market our products. To the extent that we enter into arrangements with third parties to perform marketing and distribution services, our product revenue could be lower and our costs higher than if we directly marketed our products. Furthermore, to the extent that we enter into co-promotion or other marketing and sales arrangements with other companies, any revenue received will depend on the skills and efforts of others, and we do not know whether these efforts will be successful. If we are unable to establish and maintain adequate sales, marketing and distribution capabilities, independently or with others, we will not be able to generate product revenue, and may not become profitable.
Our business could be negatively impacted by cyber security threats , including without limitation a material interruption to our operations including our clinical trials, harm to our reputation, significant fines, penalties and liabilities, breach or triggering of data protection laws, privacy policies and data protection obligations, or a loss of customers or sales.
In the ordinary course of our business, we may collect, process, store and transmit proprietary, confidential and sensitive information, including personal information (including health information), intellectual property, trade secrets, and proprietary business information owned or controlled by ourselves or other parties. We use our data centers and our networks, and those of third parties, to store and access our proprietary business and other sensitive information. We face various cyber security threats, which are prevalent and continue to increase, including cyber security attacks to our information technology infrastructure and attempts by others to gain access to our proprietary or sensitive information. Due to COVID-19, there may be additional cyber security threats as most of our employees work from home, utilizing network connections outside of the Company premises. Information security risks have significantly increased in recent years in part due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, data and related privacy breaches, terrorists and other external parties, including foreign private parties and state and state-sponsored actors.
Despite the implementation of preventative and detective security measures, our internal computer systems and those of our current and any future contractors, consultants, collaborators and third-party service providers, are vulnerable to damage or interruption from a variety of sources, including computer viruses, or worms, software bugs, employee theft or misuse, other unauthorized access, software or hardware failures, server malfunctions, accidental acts or omissions by those with authorized access, natural disasters, terrorism, war, telecommunication and electrical failure, and cybersecurity threats (including the deployment of harmful malware, ransomware, denial-of-service attacks (such as credential stuffing), supply chain attacks, social engineering, and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information). Ransomware attacks, including those from organized criminal threat actors, nation-states and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions, delays, or outages in our operations, disruption of clinical trials, loss of data (including data related to clinical trials), loss of income, significant extra expenses to restore data or systems, reputational loss and the diversion of funds. To alleviate the financial, operational and reputational impact of a ransomware attack it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including, for example, if applicable laws or regulations prohibit such payments).
The procedures and controls we use to monitor these threats and mitigate our exposure may not be sufficient to prevent all cyber security incidents. The result of these incidents could include disrupted operations, including suspension of our clinical trial activities, lost opportunities, misstated financial data, liability for stolen assets or information, theft of our intellectual property, loss of data and other personally identifiable or sensitive information, increased costs arising from the implementation of additional security protective measures, litigation and reputational damage. We may expend significant resources, fundamentally change our business activities and practices, or modify our operations, including our clinical trial activities, or information technology in an effort to protect against security incidents and to mitigate, detect, and remediate actual and potential vulnerabilities.
45

Table of Contents
If we, or a third party upon whom we rely, experience a security incident, or are perceived to have experienced a security incident, it may result in: government enforcement actions that could include investigations, fines, penalties, audits and inspections; additional reporting requirements and/or oversight; temporary or permanent bans on all or some processing of personal data (which could impact our clinical trials); or orders to destroy or not use personal data. Further, individuals or other relevant stakeholders could sue us for our actual or perceived failure to comply with our security obligations, including, without limitation, in class action litigation. Security incidents could also result in indemnity obligations, negative publicity and financial loss. Security incidents and vulnerabilities may cause some of our customers and users to stop using our services and our failure, or perceived failure, to meet expectations with regard to the security, integrity, availability and confidentiality of our systems and sensitive data could damage our reputation and affect our ability to retain customers, attract new customers and grow our business. Moreover, security incidents can result in the diversion of funds, and interruptions, delays, or outages in our operations and services, including due to ransomware attacks. Failures or significant downtime of our information technology or telecommunication systems or those used by our third-party service providers could cause significant interruptions in our operations and adversely impact the confidentiality, integrity and availability of sensitive or confidential information, including preventing us from conducting clinical trials, tests or research and development activities and preventing us from managing the administrative aspects of our business.
Any remedial costs or other liabilities related to cyber security incidents may not be fully insured or indemnified by other means. Additionally, some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses and remediation costs.
Compliance with stringent and changing global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and, if applicable, process data globally, and the failure or perceived failure to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.
We collect, receive, store, process, use, generate, transfer, disclose, make accessible, protect and share personal information and other sensitive information, including but not limited to proprietary and confidential business information, trade secrets, intellectual property, information we collect about patients in connection with clinical trials, and sensitive third-party information, necessary to operate our business, for legal and marketing purposes. Accordingly, we are, or may become, subject to numerous federal, state, local, and international data privacy and security laws, regulations, guidance and industry standards as well as external and internal privacy and security policies, contracts and other obligations that apply to the processing of personal data by us and on our behalf. The legal framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future.
For example, the European Union’s General Data Protection Regulation (“GDPR”) imposes strict obligations on the processing of personal data, including, without limitation, personal health data, and the free movement of such data. The GDPR applies to any company established in the European Union as well as any company outside the European Union that processes personal data in connection with the offering of goods or services to individuals in the European Union or the monitoring of their behavior. The GDPR imposes data protection obligations on processors and controllers of personal data, including, for example, obligations relating to: processing health and other sensitive data; obtaining consent of individuals; providing notice to individuals regarding data processing activities; responding to data subject requests; taking certain measures when engaging third-party processors; notifying data subjects and regulators of data breaches; implementing safeguards to protect the security and confidentiality of personal data; and transferring personal data to countries outside the European Union, including the U.S. The GDPR imposes fines for breaches of data protection requirements and provides other remedies for parties who suffer harm as a result of a data breach. Furthermore, the vote in the United Kingdom in favor of exiting the European Union, referred to as Brexit, has complicated data protection regulation in the United Kingdom. As of January 1, 2021, the GDPR has been converted into United Kingdom law and the United Kingdom is now a “third country” under the GDPR. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices or lead to government enforcement actions, private litigation or significant penalties against us and could have a material adverse effect on our business, financial condition or results of operations.
46

Table of Contents
Similarly, European data protection laws also generally prohibit the transfer of personal data from Europe, to countries outside the European Economic Area ("EEA"), such as the United States, unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. One of the primary safeguards used for transfers of personal data from the European Union to the United States, namely, the Privacy Shield framework administered by the U.S. Department of Commerce, was recently invalidated by a decision of the European Union’s highest court. The same decision also cast doubt on the ability to use one of the primary alternatives to the Privacy Shield, namely, the European Commission’s Standard Contractual Clauses, to lawfully transfer personal data from Europe to the United States and most other countries. On June 4, 2021, the European Commission adopted new SCCs under the GDPR for personal data transfers outside the EEA. Under this legal mechanism, we may have obligations to conduct transfer impact assessments for such cross-border data transfers and implement additional security measures. If we elect to rely on the new SCCs, we may be required to expend significant resources to update our contractual arrangements and to comply with such obligations.
In addition, Swiss and English law contain similar data transfer restrictions as the GDPR, and the Swiss Federal Data Protection and Information Commissioner recently opined that the Swiss-U.S. Privacy Shield may also be inadequate for transfers of data from Switzerland to the United States. As for the United Kingdom, on June 28, 2021, the European Commission issued an adequacy decision under the GDPR which allows transfers (other than those carried out for the purposes of United Kingdom immigration control) of personal data from the EEA to the United Kingdom to continue without restriction for a period of four years ending June 27, 2025. After that period, the adequacy decision may be renewed, however, only if the United Kingdom continues to ensure an adequate level of data protection. During these four years, the European Commission will continue to monitor the legal situation in the United Kingdom and could intervene at any point if the United Kingdom deviates from the level of data protection in place at the time of issuance of the adequacy decision. If the adequacy decision is withdrawn or not renewed, transfers of personal data from the EEA to the United Kingdom will require a valid ‘transfer mechanism’ and we may be required to implement new processes and put new agreements in place, such as SCCs, to enable transfers of personal data from the EEA to the United Kingdom to continue. If we are unable to implement a valid compliance mechanism for cross-border personal information transfers, we may face increased exposure to regulatory actions, substantial fines and injunctions against processing or transferring personal information from Europe or elsewhere. Inability to import personal information from Europe or elsewhere to the United States may significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with Contract Research Organizations, service providers, contractors and other companies subject to European and other data protection laws; or requiring us to increase our data processing capabilities in Europe or elsewhere at significant expense.
Additionally, the California Consumer Privacy Act (the “CCPA”), creates new individual privacy rights for consumers and places increased privacy and security obligations on entities handling personal data of consumers. Among other things, the CCPA requires covered companies to provide new disclosures to California consumers and provides such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for penalties for violations, as well as other remedies for parties who suffer harm as a result of a data breach, which may increase data breach litigation. Moreover, effective starting on January 1, 2023, the California Privacy Rights Act (“CPRA”) will significantly modify the CCPA, including by expanding consumers’ rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. Although there are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities depending on how they are interpreted. In addition, other states have enacted or proposed data privacy laws, which could further complicate the legal landscape. For example, Virginia recently passed its Consumer Data Protection Act, and Colorado recently passed the Colorado Privacy Act, both effective 2023. Collectively, these laws may increase our compliance costs and potential liability. Although we endeavor to comply with our published policies, other documentation, and all applicable privacy and security laws, we may at times fail to do so or may be perceived to have failed to do so. If we fail, or are perceived to have failed, to address or comply with obligations related to data privacy and security, we could face government enforcement actions that could include investigations, fines, penalties, audits and inspections; additional reporting requirements and/or oversight; temporary or permanent bans on all or some processing of personal data; orders to destroy or not use personal data; and imprisonment of company officials. Further, individuals or other relevant stakeholders could sue us for our actual or perceived failure to comply with our data privacy and security obligations, including, without limitation, in class action litigation. Any of these events could have a material adverse effect on our reputation, business, or financial condition, and could lead to a loss of actual or prospective customers, collaborators or partners; interrupt or stop clinical trials; result in an inability to process personal data or to operate in certain jurisdictions; limit our ability to develop or commercialize our products; or require us to revise or restructure our operations. Moreover, such suits, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business or have other material adverse effects. Additionally, we expect that there will continue to be new proposed laws and regulations concerning data privacy and security, and we cannot yet determine the impact such future laws, regulations and standards may have on our business.
47

Table of Contents
*Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.
Maintaining effective internal control over financial reporting is necessary for us to produce reliable financial statements. Our management previously identified a material weakness in our internal control over financial reporting and concluded that the material weakness has not been remediated and our disclosure controls and procedures were not effective as of June 30, 2021. The material weakness in internal control over financial reporting resulted from a deficiency in our disclosure controls and procedures which could have resulted in us not disclosing a material potential loss requiring a qualitative disclosure and recording a liability in our consolidated financial statements under ASC 450 - Contingencies. If not remediated, or if we identify further material weaknesses in our internal controls, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common stock.
We are subject to financial and operating covenants in our business financing agreement with Western Alliance Bank (the “Credit Agreement”) and any failure to comply with such covenants, or obtain waivers in the event of non-compliance, could limit our borrowing availability under the Credit Agreement, resulting in our being unable to borrow under the Credit Agreement and materially adversely impact our liquidity. In addition, our operations may not provide sufficient cash to meet the repayment obligations of debt incurred under the Credit Agreement.
The Credit Agreement contains affirmative and restrictive covenants, including covenants regarding delivery of financial statements, maintenance of inventory, payment of taxes, maintenance of insurance, dispositions of property, business combinations or acquisitions and incurrence of additional indebtedness, among other customary covenants, in each case subject to limited exceptions.
There can be no assurance that we will be able to comply with the financial and other covenants in the Credit Agreement, and the effects of COVID-19 may make it more difficult for us to comply with such covenants. Our failure to comply with these covenants could cause us to be unable to borrow under the Credit Agreement and may constitute an event of default which, if not cured or waived, could result in the acceleration of the maturity of any indebtedness then outstanding under the Credit Agreement, which would require us to pay all amounts then outstanding. If we are unable to repay those amounts, Western Alliance Bank could proceed against the collateral granted to them to secure that debt, which would seriously harm our business. Such an event could materially adversely affect our financial condition and liquidity. Additionally, such events of non-compliance could impact the terms of any additional borrowings and/or any credit renewal terms. Any failure to comply with such covenants may be a disclosable event and may be perceived negatively. Such perception could adversely affect the market price for our common stock and our ability to obtain financing in the future.
Risks Related to Regulatory Approval of Our Products and Other Government Regulations
We are subject to regulation by various federal, state and foreign agencies that require us to comply with a wide variety of regulations, including those regarding the manufacture of products, advertising and product label claims, the distribution of our products and environmental matters. Failure to comply with these regulations could subject us to fines, penalties and additional costs.
Some of our operations are subject to regulation by various United States federal agencies and similar state and international agencies, including the Department of Commerce, the FDA, the FTC, the Department of Transportation and the Department of Agriculture. These regulations govern a wide variety of product activities, from design and development to labeling, manufacturing, handling, sales and distribution of products. If we fail to comply with any of these regulations, we may be subject to fines or penalties, have to recall products and/or cease their manufacture and distribution, which would increase our costs and reduce our sales. As disclosed above, we received the Letter from the FDA and FTC in November 2020, and the Second Letter from the FTC in April 2021.
We are also subject to various federal, state, local and international laws and regulations that govern the handling, transportation, manufacture, use and sale of substances that are or could be classified as toxic or hazardous substances. Some risk of environmental damage is inherent in our operations and the products we manufacture, sell, or distribute. Any failure by us to comply with the applicable government regulations could also result in product recalls or impositions of fines and restrictions on our ability to carry on with or expand in a portion or possibly all of our operations. If we fail to comply with any or all of these regulations, we may be subject to fines or penalties, have to recall products and/or cease their manufacture and distribution, which would increase our costs and reduce our sales.
48

Table of Contents
Government regulations of our customer’s business are extensive and are constantly changing. Changes in these regulations can significantly affect customer demand for our products and services.
The process by which our customers’ industries are regulated is controlled by government agencies and depending on the market segment can be very expensive, time consuming, and uncertain. Changes in regulations or the enforcement practices of current regulations could have a negative impact on our customers and, in turn, our business. At this time, it is unknown how the FDA will interpret and to what extent it will enforce GMPs, and other regulations that will likely affect many of our customers. These uncertainties may have a material impact on our results of operations, as lack of enforcement or an interpretation of the regulations that lessens the burden of compliance for the dietary supplement marketplace may cause a reduced demand for our products and services.
Changes in government regulation or in practices relating to the pharmaceutical, dietary supplement, food and cosmetic industry could decrease the need for the services we provide.
Governmental agencies throughout the world, including in the United States, strictly regulate the pharmaceutical, dietary supplement, food and cosmetic industries. Changes in regulation, such as a relaxation in regulatory requirements or the introduction of simplified drug approval procedures, or an increase in regulatory requirements that we have difficulty satisfying or that make our services less competitive, could eliminate or substantially reduce the demand for our services. Also, if the government makes efforts to contain drug costs and pharmaceutical and biotechnology company profits from new drugs, our customers may spend less, or reduce their spending on research and development. If health insurers were to change their practices with respect to reimbursements for pharmaceutical products, our customers may spend less, or reduce their spending on research and development.
If we should in the future become required to obtain regulatory approval to market and sell our goods we will not be able to generate any revenues until such approval is received.
The pharmaceutical industry is subject to stringent regulation by a wide range of authorities. While we believe that, given our present business, we are not currently required to obtain regulatory approval to market our goods because, among other things, we do not (i) produce or market any clinical devices or other products, or (ii) sell any medical products or services to the customer, we cannot predict whether regulatory clearance will be required in the future and, if so, whether such clearance will at such time be obtained for any products that we are developing or may attempt to develop. Should such regulatory approval in the future be required, our goods may be suspended or may not be able to be marketed and sold in the United States until we have completed the regulatory clearance process as and if implemented by the FDA. Satisfaction of regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of the product or service and would require the expenditure of substantial resources.
If regulatory clearance of a good that we propose to propose to market and sell is granted, this clearance may be limited to those particular states and conditions for which the good is demonstrated to be safe and effective, which would limit our ability to generate revenue. We cannot ensure that any good that we develop will meet all of the applicable regulatory requirements needed to receive marketing clearance. Failure to obtain regulatory approval will prevent commercialization of our goods where such clearance is necessary. There can be no assurance that we will obtain regulatory approval of our proposed goods that may require it.
49

Table of Contents
Risks Related to the Securities Markets and Ownership of our Equity Securities
The market price of our common stock may be volatile and adversely affected by several factors.
The market price of our common stock could fluctuate significantly in response to various factors and events, including, but not limited to:
•our ability to integrate operations, technology, products and services;
•our ability to execute our business plan;
•our operating results are below expectations;
•our issuance of additional securities, including debt or equity or a combination thereof;
•announcements of technological innovations or new products by us or our competitors;
•acceptance of and demand for our products by consumers;
•media coverage regarding our industry or us;
•litigation;
•disputes with or our inability to collect from significant customers;
•loss of any strategic relationship;
•industry developments, including, without limitation, changes in healthcare policies or practices;
•economic and other external factors, including effects of the COVID-19 pandemic;
•reductions in purchases from our large customers;
•period-to-period fluctuations in our financial results; and
•whether an active trading market in our common stock develops and is maintained.
In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.
We have not paid cash dividends in the past and do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.
We have never paid cash dividends on our capital stock and do not anticipate paying cash dividends on our capital stock in the foreseeable future. The payment of dividends on our capital stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as the board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if the common stock price appreciates.
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
Our federal net operating losses (“NOL”s) generated in taxable years beginning on or prior to December 31, 2017 could expire unused. Under legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") federal NOLs incurred in taxable years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. As a result, if we earn net taxable income, our ability to use our pre-ownership change NOL carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California imposed limits on the usability of California state net operating losses to offset taxable income in tax years beginning after 2019 and before 2023.
50

Table of Contents
*We have a significant number of outstanding options and unvested restricted stock units. Future sales of these shares could adversely affect the market price of our common stock.
As of June 30, 2021, we had outstanding options for an aggregate of approximately 10.5 million shares of common stock at a weighted average exercise price of $4.52 per share and unvested restricted stock units of approximately 0.1 million shares. The holders may sell many of these shares in the public markets from time to time, without limitations on the timing, amount or method of sale. As and when our stock price rises, if at all, more outstanding options will be in-the-money and the holders may exercise their options and sell a large number of shares. This could cause the market price of our common stock to decline.
Our amended and restated bylaws, as amended (our “Bylaws”) provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Our Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to our company or our stockholders, (iii) any action asserting a claim against our company arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or Bylaws, or (iv) any action asserting a claim against our company governed by the internal affairs doctrine. This choice of forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.
This choice of forum provision may limit a stockholder’s ability to bring certain claims in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. If a court were to find this choice of forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition
General Risks
We may become involved in securities class action litigation that could divert management’s attention and harm our business.
The stock market in general, and the stocks of early stage companies in particular, have experienced extreme price and volume fluctuations. These fluctuations have often been unrelated or disproportionate to the operating performance of the companies involved. If these fluctuations occur in the future, the market price of our shares could fall regardless of our operating performance. In the past, following periods of volatility in the market price of a particular company’s securities, securities class action litigation has often been brought against that company. If the market price or volume of our shares suffers extreme fluctuations, then we may become involved in this type of litigation, which would be expensive and divert management’s attention and resources from managing our business.
As a public company, we may also from time to time make forward-looking statements about future operating results and provide some financial guidance to the public markets. Projections may not be made in a timely manner or we might fail to reach expected performance levels and could materially affect the price of our shares. Any failure to meet published forward-looking statements that adversely affect the stock price could result in losses to investors, stockholder lawsuits or other litigation, sanctions or restrictions issued by the Securities and Exchange Commission.
51

Table of Contents
Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.
New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act, enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Cuts and Jobs Act may affect us, and certain aspects of the Tax Cuts and Jobs Act could be repealed or modified in future legislation. For example, the CARES Act modified certain provisions of the Tax Cuts and Jobs Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act, the CARES Act, or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Cuts and Jobs Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.
Our shares of common stock may be thinly traded, so you may be unable to sell at or near ask prices or at all.
We cannot predict the extent to which an active public market for our common stock will develop or be sustained. This situation may be attributable to a number of factors, including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community who generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we have become more seasoned and viable. As a consequence, there may be periods of several days or weeks when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot assure you that a broader or more active public trading market for our common stock will develop or be sustained, or that current trading levels will be sustained or not diminish.
Stockholders may experience significant dilution if future equity offerings are used to fund operations or acquire complementary businesses.
If future operations or acquisitions are financed through the issuance of additional equity securities, stockholders could experience significant dilution. Securities issued in connection with future financing activities or potential acquisitions may have rights and preferences senior to the rights and preferences of our common stock. In addition, the issuance of shares of our common stock upon the exercise of outstanding options or warrants may result in dilution to our stockholders.
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
Item 3. Defaults upon Senior Securities
None.
Item 4. MINE SAFETY DISCLOSURES
Not applicable.
Item 5. Other Information
Effective as of August 2, 2021, the Company entered into a Seventh Amendment (the “Seventh Amendment”) to the Manufacturing and Supply Agreement (such agreement as amended, the “Grace Manufacturing Agreement”), originally effective in January 2016, with W.R. Grace & Co. –Conn. Pursuant to the Seventh Amendment, the Company is obligated to purchase approximately $18.0 million of total inventory between January 1, 2022 and December 31, 2022 and $3.5 million of inventory from January 1, 2023 through June 30, 2023. The Grace Manufacturing Agreement will expire on June 30, 2023, subject to renewal periods to be negotiated by the parties.
52

Table of Contents
Item 6. Exhibits

Exhibit No. |  | Description of Exhibits
2.1 |  | Agreement and Plan of Merger, dated as of May 21, 2008, by and among Cody Resources, Inc., CDI Acquisition, Inc. and ChromaDex, Inc., as amended on June 10, 2008 (incorporated by reference to, and filed as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K (File No. 333-140056) filed with the Commission on June 24, 2008) (1)
2.2 |  | Asset Purchase Agreement, dated as of August 21, 2017, by and among Covance Laboratories Inc., ChromaDex, Inc., ChromaDex Analytics, Inc., and ChromaDex Corporation (incorporated by reference from, and filed as Exhibit 2.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37752) filed with the Commission on November 9, 2017)*
2.3 |  | Amendment to Asset Purchase Agreement, dated as of September 5, 2017, by and among Covance Laboratories Inc., ChromaDex, Inc., ChromaDex Analytics, Inc., and ChromaDex Corporation (incorporated by reference from, and filed as Exhibit 2.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37752) filed with the Commission on November 9, 2017)
3.1 |  | Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to, and filed as Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K (File No. 001-37752) filed with the Commission on March 15, 2018)
3.2 |  | Bylaws of the Registrant (incorporated by reference to, and filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 333-140056) filed with the Commission on June 24, 2008)
3.3 |  | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to, and filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 000-53290) filed with the Commission on April 12, 2016)
3.4 |  | Amendment to Bylaws of the Registrant (incorporated by reference to, and filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37752) filed with the Commission on July 19, 2016)
4.1 |  | Form of Stock Certificate representing shares of the Registrant’s Common Stock (incorporated by reference to, and filed as Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K (File No. 000-53290) filed with the Commission on April 3, 2009)
4.2 |  | Investor’s Rights Agreement, effective as of December 31, 2005, by and between The University of Mississippi Research Foundation and the Registrant (incorporated by reference to, and filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 333-140056) filed with the Commission on June 24, 2008)
4.3 |  | Tag-Along Agreement effective as of December 31, 2005, by and among the Registrant, Frank Louis Jaksch, Snr. & Maria Jaksch, Trustees of the Jaksch Family Trust, Margery Germain, Lauren Germain, Emily Germain, Lucie Germain, Frank Louis Jaksch, Jr., and the University of Mississippi Research Foundation (incorporated by reference to, and filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K (File No. 333-140056) filed with the Commission on June 24, 2008)
4.4 |  | Form of Stock Certificate representing shares of the Registrant’s Common Stock effective as of January 1, 2016 (incorporated by reference to, and filed as Exhibit 4.4 to the Registrant’s Annual Report on Form 10-K (File No. 001-37752) filed with the Commission on March 17, 2016)
4.5 |  | Form of Stock Certificate representing shares of the Registrant’s Common Stock effective as of December 10, 2018 (incorporated by reference to, and filed as Exhibit 4.5 to the Registrant’s Annual Report on Form 10-K (File No. 001-37752) filed with the Commission on March 7, 2019)
4.6 |  | Registration Rights Agreement, dated as of May 9, 2019, by and among the Registrant and the parties thereto (incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 10, 2019)
4.7 |  | Registration Rights Agreement, dated as of August 15, 2019, by and among the Registrant and the parties thereto (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 15, 2019)
4.8 |  | Registration Rights Agreement, dated as of April 27, 2020, by and among the Registrant and the parties thereto (incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on April 29, 2020)
4.9 |  | Registration Rights Agreement, dated February 20, 2021, by and among the Company and the Purchaser (incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 22, 2021)
10.1 |  | Fifth Amendment to Lease, dated May 21, 2021, by and between 10900 WILSHIRE L.L.C and ChromaDex, Inc. ❖
10.2 |  | License Agreement, dated July 5, 2011 between ChromaDex, Inc. and Cornell University ** v

53

Table of Contents

Exhibit No. |  | Description of Exhibits
10.3 |  | Seventh Amendment to Manufacturing and Supply Agreement, dated as of August 2, 2021, by and between ChromaDex Inc. and W.R. Grace & Co.-Conn. ❖ **
31.1 |  | Certification of the Chief Executive Officer pursuant to Rule 13a-14(A) of the Securities Exchange Act of 1934, as amended❖
31.2 |  | Certification of the Chief Financial Officer pursuant to Rule 13a-14(A) of the Securities Exchange Act of 1934, as amended❖
32.1 |  | Certification pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002)❖
101.INS |  | Inline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 |  | 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

v Filed herewith.
(1) Plan and related Forms were assumed by ChromaDex Corporation pursuant to Agreement and Plan of Merger, dated as of May 21, 2008, among ChromaDex Corporation (formerly Cody Resources, Inc.), CDI Acquisition, Inc. and ChromaDex, Inc.
* This exhibit has been granted confidential treatment and has been filed separately with the Commission. The confidential portions of this exhibit have been omitted and are marked by an asterisk.
** Certain portions of this exhibit (indicated by asterisks) have been excluded pursuant to Item 601(b)(10) of Regulation S-K because they are both not material and are the type that the Registrant treats as private or confidential.
54

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  | CHROMADEX CORPORATION
Date: August 3, 2021 |  | /s/ KEVIN M. FARR
|  | Kevin M. Farr
|  | Chief Financial Officer
|  | (principal financial and accounting officer and duly authorized on behalf of the registrant)

55